<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2108234016
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Byannli
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PALIPERIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        700
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6947.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN PHARMACEUTICA N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BYANNLI contains the active substance paliperidone which belongs to the class of antipsychotic medicines.</p><p>&nbsp;</p><p>BYANNLI is used as a maintenance treatment for the symptoms of schizophrenia in adult patients.</p><p>&nbsp;</p><p>If you have responded well to treatment with paliperidone palmitate injection given once a month or once every three months, your doctor may start treatment with BYANNLI.</p><p>Schizophrenia is a disease with &ldquo;positive&rdquo; and &ldquo;negative&rdquo; symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that are not there (called hallucinations), believe things that are not true (called delusions), or feel unusually suspicious of others. Negative means a lack of behaviours or feelings that are normally present. For example, a person with schizophrenia may appear withdrawn and may not respond at all emotionally or may have trouble speaking in a clear and logical way. People with this disease may also feel depressed, anxious, guilty, or tense.</p><p>&nbsp;</p><p>BYANNLI can help alleviate the symptoms of your disease and reduce the risk of your symptoms coming back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use BYANNLI</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to paliperidone or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to risperidone.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using BYANNLI.</p><p>&nbsp;</p><p>This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death (see section 4).</p><p>&nbsp;</p><p>All medicines have side effects and some of the side effects of this medicine can worsen the symptoms of other medical conditions. For that reason, it is important to discuss with your doctor any of the following conditions which can potentially worsen during treatment with this medicine:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have Parkinson&rsquo;s disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a type of dementia called &ldquo;Lewy body dementia&rdquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as Neuroleptic Malignant Syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever experienced twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body (Tardive Dyskinesia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are diabetic or prone to diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had breast cancer or a tumour in the pituitary gland in your brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a heart disease or heart disease treatment that makes you prone to low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood pressure when you stand up or sit up suddenly</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of seizures</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have prolonged and/or painful erection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with controlling body temperature or overheating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin-dependent tumour</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots.</p><p>&nbsp;</p><p>If you have any of these conditions, please talk to your doctor as he/she may want to adjust your dose or monitor you for a while.</p><p>As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking this medicine, your doctor may check your white blood cell counts.</p><p>&nbsp;</p><p>Even if you have previously tolerated oral paliperidone or risperidone, rarely allergic reactions occur after receiving injections of BYANNLI. Seek medical attention right away if you experience a rash, swelling of your throat, itching, or problems breathing as these may be signs of a serious allergic reaction.</p><p>&nbsp;</p><p>This medicine may cause you to gain or loose weight. Significant changes in weight may be bad for your health. Your doctor should regularly measure your body weight.</p><p>&nbsp;</p><p>As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients taking this medicine, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus blood glucose should be monitored regularly.</p><p>&nbsp;</p><p>Since this medicine may reduce your urge to vomit, there is a chance that it may mask the body&rsquo;s normal response to ingestion of toxic substances or other medical conditions.</p><p>&nbsp;</p><p><strong>Cataract operations</strong></p><p>If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine. This is because during a cataract operation on the eye for cloudiness of the lens:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the pupil (the black circle in the middle of your eye) may not increase in size as needed</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the iris (the coloured part of the eye) may become floppy during surgery and that may lead to eye damage.</p><p><strong>Children and adolescents</strong></p><p>Do not use this medicine in children and adolescents under 18 years of age. It is not known if it is safe and effective in these patients.</p><p>&nbsp;</p><p><strong>Other medicines and BYANNLI</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Taking this medicine with carbamazepine (an anti-epileptic and mood stabiliser) may require a change to your dose of this medicine.</p><p>Since this medicine works primarily in the brain, using other medicines that work in the brain can cause an exaggeration of side effects such as sleepiness or other effects on the brain such as other psychiatric medicines, opioids, antihistamines and sleep medicines.</p><p>&nbsp;</p><p>Tell your doctor if you take this medicine while you are also taking oral risperidone or paliperidone for extended periods of time. You may require a change to your dose of BYANNLI.</p><p>Since this medicine can lower blood pressure, care should be taken when this medicine is used with other medicines that lower blood pressure.</p><p>This medicine can reduce the effect of medicines against Parkinson&rsquo;s disease and restless legs syndrome (e.g., levodopa).</p><p>This medicine may cause an electrocardiogram (ECG) abnormality demonstrating a long time for an electrical impulse to travel through a certain part of the heart (known as &ldquo;QT prolongation&rdquo;). Other medicines that have this effect include some medicines used to treat the rhythm of the heart or to treat infection, and other antipsychotics.</p><p>&nbsp;</p><p>If you have a history of seizures, this medicine may increase your risk of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infection, and other antipsychotics.</p><p>&nbsp;</p><p>BYANNLI should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).</p><p><strong>BYANNLI with alcohol</strong></p><p>Alcohol should be avoided.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><em>Women of childbearing potential</em></p><p>A single dose of this medicine is expected to remain within the body for up to 4 years, which may be a risk for the baby. BYANNLI should, therefore, only be used in women planning to have a baby if clearly necessary.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>You should not use this medicine during pregnancy unless this has been discussed with your doctor. The following symptoms may occur in newborn babies of mothers that have used paliperidone in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. Newborns should be monitored carefully and if your baby develops any of these symptoms seek medical attention for your baby.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>This medicine can pass from mother to baby through breast milk. It may harm the baby, even a long time after the latest dose. Therefore, you should not breast-feed if you are using, or have used, this medicine in the past 4 years.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Dizziness, extreme tiredness and vision problems may occur during treatment with this medicine (see section 4). This should be considered in cases where full alertness is required, e.g., when driving a car or handling machines.</p><p>&nbsp;</p><p><strong>BYANNLI contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is administered by your doctor or other healthcare professional. Your doctor will tell you when you need your next injection. It is important not to miss your scheduled dose. If you cannot keep your appointment, make sure you call right away so another appointment can be made as soon as possible.</p><p>&nbsp;</p><p>You will receive an injection of BYANNLI in the buttocks once every 6 months.</p><p>&nbsp;</p><p>Depending on your symptoms, your doctor may increase or decrease the amount of medicine you receive at the time of your next scheduled injection.</p><p>&nbsp;</p><p><u>Patients with kidney problems</u></p><p>If you have mild kidney problems your doctor will determine if BYANNLI is appropriate based on the dose of 1-monthly or 3-monthly paliperidone palmitate injectable that you have been receiving. The</p><p>1 000 mg dose of BYANNLI is not recommended.</p><p>If you have moderate or severe kidney problems this medicine should not be used.</p><p><u>Elderly</u></p><p>Your doctor may adjust your dose of this medicine if your kidney function is reduced.</p><p>&nbsp;</p><p><strong>If you are given more BYANNLI than needed</strong></p><p>This medicine will be given to you under medical supervision; it is, therefore, unlikely that you will be given too much.</p><p>Patients who have been given too much paliperidone may experience the following symptoms: drowsiness or sedation, fast heart rate, low blood pressure, an abnormal electrocardiogram (electrical tracing of the heart), or slow or abnormal movements of the face, body, arms or legs.</p><p>&nbsp;</p><p><strong>If you stop using BYANNLI</strong></p><p>If you stop receiving your injections, your symptoms of schizophrenia may get worse. You should not stop using this medicine unless told to do so by your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>If you get any of the following serious side effects, you may need immediate medical treatment. Tell your doctor or go to the nearest hospital straight away:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the veins, especially in the legs. This is rare (may affect up to 1 in 1 000 people). Symptoms include:</p><p>o&nbsp;&nbsp; swelling, pain, and redness in the leg &ndash; &ldquo;deep vein thrombosis&rdquo;</p><p>o&nbsp;&nbsp; chest pain and difficulty breathing caused by blood clots that travelled through blood vessels to the lungs &ndash; &ldquo;pulmonary embolism&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of a stroke, the frequency is not known (cannot be estimated from the available data). Symptoms include:</p><p>o&nbsp;&nbsp; sudden change in your mental state</p><p>o&nbsp;&nbsp; sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuroleptic malignant syndrome. This is rare (may affect up to 1 in 1 000 people). Symptoms include:</p><p>o&nbsp;&nbsp; Fever, muscle stiffness, sweating or a lowered level of consciousness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged erection, which may be painful (priapism). This is rare (may affect up to 1 in 1 000 people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twitching or jerking rhythmic movements that you cannot control in your tongue, mouth and face or other parts of your body (Tardive Dyskinesia). This is uncommon (may affect up to 1 in 100 people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction (anaphylactic reaction), the frequency is not known (cannot be estimated from the available data). Symptoms include:</p><p>o&nbsp;&nbsp; fever,</p><p>o&nbsp;&nbsp; swollen mouth, face, lip or tongue,</p><p>o&nbsp;&nbsp; shortness of breath,</p><p>o&nbsp; itching, skin rash and sometimes drop in blood pressure.</p><p>Even if you have previously tolerated oral risperidone or oral paliperidone, rarely allergic reactions occur after receiving injections of paliperidone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Floppy iris syndrome, when the iris (the coloured part of the eye) become floppy during eye cataract surgery. This may lead to eye damage (see also &lsquo;<em>Cataract operations</em>&rsquo; in section 2). The frequency is not known (cannot be estimated from the available data).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome or toxic epidermal necrolysis. Severe or life-threatening rash with blisters and peeling skin that may start in and around the mouth, nose, eyes and genitals and spread to other areas of the body. The frequencies are not known (cannot be estimated from the available data).</p><p>Tell your doctor straight away or go to the nearest hospital immediately if you notice any of the serious side effects above.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agranulocytosis, dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood. The frequency of this is not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p><strong>Very common side effects: may affect more than 1 in 10 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty falling or staying asleep.</p><p><strong>Common side effects: may affect up to 1 in 10 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common cold symptoms, urinary tract infection, feeling like you have the flu.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BYANNLI can raise your levels of a hormone called &ldquo;prolactin&rdquo; found on a blood test (which may or may not cause symptoms). When symptoms of high prolactin occur, they may include: (in men) breast swelling, difficulty in getting or maintaining erections, or other sexual dysfunction; (in women) breast discomfort, missed menstrual periods, or other problems with your cycle.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar, weight gain, weight loss, decreased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability, depression, anxiety.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parkinsonism: This condition may include slow or impaired movement, sensation of stiffness or tightness of the muscles (making your movements jerky), and sometimes even a sensation of movement &ldquo;freezing up&rdquo; and then restarting. Other signs of parkinsonism include a slow shuffling walk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling restless, sleepy, or less alert.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dystonia: This is a condition involving slow or sustained involuntary contraction of muscles. While it can involve any part of the body (and may result in abnormal posture), dystonia often involves muscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dyskinesia: This is a condition involving involuntary muscle movements, and can include repetitive, spastic or writhing movements, or twitching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor (shaking).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid heart rate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, stuffy nose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, vomiting, nausea, constipation, diarrhoea, indigestion, toothache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased liver transaminases in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone or muscle ache, back pain, joint pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of menstrual periods.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, weakness, fatigue (tiredness).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reaction at the injection site, including itching, pain or swelling.</p><p><strong>Uncommon side effects: may affect up to 1 in 100 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia, infection of the chest (bronchitis), infection of the breathing passages, sinus infection, bladder infection, ear infection, tonsillitis, fungal infection of the nails, infection of the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; white blood cell count decreased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes or worsening of diabetes, increased insulin (a hormone that controls blood sugar levels) in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite resulting in malnutrition and low body weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood triglycerides (a fat), increased cholesterol in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disorder, elated mood (mania), decreased sexual drive, nervousness, nightmares.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, a restless urge to move parts of your body, dizziness upon standing, disturbance in attention, problems with speech, loss or abnormal sense of taste, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness of skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurry vision, eye infection or &ldquo;pink eye&rdquo;, dry eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of spinning (vertigo), ringing in the ears, ear pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an interruption in conduction between the upper and lower parts of the heart, abnormal electrical conduction of the heart, prolongation of the QT interval from your heart, rapid heartbeat upon standing, slow heart rate, abnormal electrical tracing of the heart (electrocardiogram or ECG), a fluttering or pounding feeling in your chest (palpitations).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, low blood pressure upon standing (consequently, some people taking this medicine may feel faint, dizzy, or may pass out when they stand up or sit up suddenly).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, sore throat, nosebleeds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal discomfort, stomach or intestinal infection, difficulty swallowing, dry mouth, excessive passing of gas or wind.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, increased liver enzymes in your blood.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (or &ldquo;nettle rash&rdquo;), itching, rash, hair loss, eczema, dry skin, skin redness, acne, abscess under the skin, flaky, itchy scalp or skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase of CPK (creatine phosphokinase), an enzyme in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, joint stiffness, muscle weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; incontinence (lack of control) of urine, frequent passing of urine, pain when passing urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erectile dysfunction, ejaculation disorder, missed menstrual periods or other problems with your cycle (females), development of breasts in men, sexual dysfunction, breast pain, leakage of milk from the breasts.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, mouth, eyes, or lips, swelling of the body, arms, or legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in body temperature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in the way you walk.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, chest discomfort, feeling unwell.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hardening of the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fall.</p><p><strong>Rare side effects: may affect up to 1 in 1 000 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin inflammation caused by mites.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in eosinophils (a type of white blood cell) in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in platelets (blood cells that help you stop bleeding).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inappropriate secretion of a hormone that controls urine volume.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sugar in the urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening complications of uncontrolled diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive drinking of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not moving or responding while awake (catatonia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep walking.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of emotion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to reach orgasm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unresponsive to stimuli, loss of consciousness, low level of consciousness, convulsion (fits), balance disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal coordination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glaucoma (increased pressure within the eyeball).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with movement of your eyes, eye rolling, oversensitivity of the eyes to light, increased tears, redness of the eyes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; head shaking that you cannot control.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atrial fibrillation (an abnormal heart rhythm), irregular heartbeat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing during sleep (sleep apnoea).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung congestion, congestion of breathing passages.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crackly lung sounds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen tongue,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stool incontinence, very hard stool, a blockage in the bowels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chapped lips.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash on skin related to drug, thickening of skin, dandruff.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint swelling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue (&ldquo;rhabdomyolysis&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to pass urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast discomfort, enlargement of the glands in your breasts, breast enlargement.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal discharge.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very low body temperature, chills, feeling thirsty.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of drug withdrawal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of pus caused by infection at injection site, deep skin infection, a cyst at the injection site, bruising at injection site.</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dangerously excessive intake of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep-related eating disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coma due to uncontrolled diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast, shallow breathing, pneumonia caused by inhaling food, voice disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased oxygen in parts of your body (because of decreased blood flow).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of bowel movement that causes blockage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and the eyes (jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin discolouration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal posture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; newborn babies born to mothers who have taken BYANNLI during pregnancy may experience side effects of the medicine and/or withdrawal symptoms, such as irritability, slow, or sustained muscle contractions, shaking, sleepiness, breathing, or feeding problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in body temperature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dead skin cells at injection site, an ulcer at injection site.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Do not store above 30&deg;C.</strong></p><p>Ship and store in a horizontal position. See arrows on product carton for proper orientation.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is paliperidone.</p><p>Each BYANNLI 700 mg pre-filled syringe contains 1 092 mg paliperidone palmitate equivalent to 700 mg paliperidone in 3.5 mL.</p><p>Each BYANNLI 1 000 mg pre-filled syringe contains 1 560 mg paliperidone palmitate equivalent to 1 000 mg paliperidone in 5 mL.</p><p>The other ingredients are: Polysorbate 20</p><p>Polyethylene glycol 4 000.</p><p>Citric acid monohydrate.</p><p>Sodium dihydrogen phosphate monohydrate</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BYANNLI is a white to off-white prolonged-release suspension for injection in a pre-filled syringe. pH is approximately 7.0. The doctor or nurse will shake the syringe very fast to resuspend the suspension before it is given as an injection.

Each pack contains 1 pre-filled syringe and 1 needle. Not all pack sizes and concentrations may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen-Cilag International</p><p>NV Turnhoutseweg 30 B-2340</p><p>Beerse Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Janssen Pharmaceutica NV Turnhoutseweg 30</p><p>B-2340 Beerse Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on 25 May 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي حقن بيانلي على مادة باليبيريدون الفعالة التي تنتمي إلى فئة األدوية المضادة للذهان.<br />يستخدم بيانلي كعلاج مستديم لاعراض الفصام لدى المرضى البالغين.<br />إذا كنت قد أظهرت استجابة جيدة للعالج باستخدام حقن باليبيريدون بالمتات التي تُعطى مرة واحدة شهريًا أو كل ثلالثة أشهر، فقد يبدأ طبيبك العالج باستخدام بيانلي.<br />والفصام مرض له أعراض &quot;إيجابية&quot; وأخرى &quot;سلبية&quot;. وتعني الاعراض الايجابية الزيادة في الاعراض التي لا تكون<br />موجودة عادةً. على سبيل المثال، قد يسمع الشخص المصاب بالفصام أصواتًا أو قد يرى أشياء غير موجودة (يُطلق على<br />هذا الهلوسة)، أو قد يعتقد في أشياء غير حقيقية (يُطلق على هذا الاوهام) أو قد يشعر بالريبة تجاه الاخرين بشكل غير<br />معتاد. أما الاعراض السلبية فتعني النقص في السلوكيات أو المشاعر الموجودة عادةً. على سبيل المثال، قد يبدو الشخص<br />المصاب بالفصام انطوائيًا، كما أنه قد لا يستجيب عاطفيًا على الاطلاق أو قد يعاني من الصعوبة في التحدث بطريقة<br />واضحة ومنطقية. وقد يشعر المرضى المصابون بهذا المرض بالاكتئاب والقلق وقد يخامرهم الاحساس بالذنب أو التوتر.<br />يمكن أن يساعد بيانلي في تخفيف أعراض المرض لديك وتقليل خطر ظهور تلك الاعراض مجددًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا&nbsp;تستخدم بيانلي</strong><br />-إذا كانت لديك حساسية ضد باليبيريدون أو أي من المكونات الاخرى في هذا الدواء (المدرجة في الفقرة 6.)<br />-إذا كانت لديك حساسية من ريسبيريدون.<br /><strong>تحذيرات واحتياطات</strong><br />تحدث مع طبيبك أو الصيدلي أو الممرضة المتابعة لحالتك قبل استخدام بيانلي.</p><p dir="RTL">لم تتم دراسة هذا الدواء على المرضى كبار السن الذين يعانون من الخرف. ومع ذلك، فإن المرضى كبار السن الذين يعانون من الخرف، والذين يُعالجون بأنواع أخرى مشابهة لهذا الدواء، قد تزيد لديهم مخاطر الاصابة بالسكتة الدماغية أو الموت (انظر القسم4.)<br /><br />جميع الأدوية لها آثار جانبية، وبعض&nbsp;الآثار الجانبية لهذا الدواء قد تزيد أعراض بعض الحاالت الطبية الآخرى سوءًا.<br />لأجل ذلك السبب، من المهم مناقشة أي من الحالات التالية التي يُحتمل أن تسوء أثناء العلاج بهذا الدواء مع طبيبك:<br />-إذا كنت تعاني من مرض باركنسون<br />-إذا كنت تعاني من نوع من الخرف يسمى &quot;داء جسيمات ليوي&quot;<br />-إذا تم تشخيصك من قبل بحالة أعراضها تتضمن ارتفاعًا في درجة الحرارة وتصلب العضلات (المعروفة أيضًا<br />باسم المتلازمة الخبيثة للدواء المضاد للذهان)<br />-إذا كنت قد تعرضت في السابق لتشنج أو حركات ارتعاشية لا يمكنك بسببها التحكم في وجهك أو لسانك أو الأجزاء<br />الأخرى من جسمك (خلل الحركة المتأخر)<br />-إذا كنت تعلم أنك تعاني من انخفاض في مستويات خاليا الدم البيضاء في الماضي (التي قد تكون ناجمة عن الأدوية<br />اخرى أو لا)<br />-إذا كنت مصابًا بمرض السكر أو عُرضة للإصابة به<br />-إذا كنت قد عانيت من سرطان الثدي أو كان لديك ورم في الغدة النخامية في الدماغ<br />-إذا كنت مصابًا بمرض في القلب أو تتلقى علاجًا لمرض القلب الذي يعرضك للإصابة بانخفاض ضغط الدم<br />-إذا كنت تعاني من انخفاض ضغط الدم عند الوقوف أوالنهوض بشكل مفاجئ<br />-إذا كان لديك تاريخ للإصابة بنوبات الصرع<br />-إذا كنت تعاني من مشكلات في الكلى<br />-إذا كنت تعاني من مشكلات في الكبد<br />-إذا كنت تعاني من انتصاب لفترات طويلةو/أو ألم عند الإنتصاب<br />-إذا كنت تعاني من مشكلات في السيطرة على درجة حرارة الجسم أو عند الإرتفاع الزائد في درجة الحرارة<br />-إذا كنت تعاني من مستوى عال ٍ بشكل مفرط من هرمون البرولاكتين في الدم أو إذا كنت مصابًا بورم محتمل معتمد<br />على هرمون البرولاكتين<br />-إذا كنت تعاني أنت أو أي شخص آخر في عائلتك من جلطات دموية، حيث إن مضادات الذهان مرتبطة بتكوُّن<br />جلطات الدم.<br />إذا كنت تعاني من أي من هذه الحالات، يُرجى التحدث مع الطبيب المعالج لك لأنه قد يحتاج إلى تعديل جرعتك أو متابعتك<br />لفترة من الزمن.<br />نادرًا جدًا ما يحدث انخفاض شديد في أعداد نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم لدى<br />المرضى الذين يستخدمون هذا الدواء؛ لذلك قد يفحص طبيبك عدد خاليا الدم البيضاء.<br />وحتى إذا كنت قد تحملت مسبقًا تلقي الباليبيريدون أو الريسبيريدون عن طريق الفم، فنادرًا ما تحدث ردود فعل تحسسية بعد<br />الحقن ببيانلي. اطلب العناية الطبية مباشرة إذا كنت تعاني من طفح جلدي أو تورم في الحلق أو الحكة أو مشكالت في<br />التنفس حيث يمكن أن تكون هذه عالمات على رد فعل تحسسي خطير.<br />قد يتسبب هذا الدواء في زيادة وزنك أو نقصانه. قد تؤثر التغيرات الكبيرة في الوزن بشكل سيِّئ في صحتك. وعلى طبيبك<br />مراقبة وزنك بانتظام.<br />قد لوحظ ظهور مرض السكري أو تفاقم السكري موجود سابقًا في المرضى الذين يتناولون هذا الدواء، لذا ينبغي لطبيبك<br />التحقق من عالمات ارتفاع نسبة السكر في الدم. وتجب مراقبة نسبة الجلوكوز في الدم لدى المرضى المصابين بالسكري<br />من قبل بانتظام.<br />نظرًا إلى أنهذاالدواء قد يخفض رغبتك في التقيؤ، فيوجد احتمال أنه قد يُخفي استجابة الجسم الطبيعية تجاه ابتالع المواد<br />السامة والحاالت الطبية األخرى.<br />عمليات إعتام عدسة العين<br />إذا كنت تخطط لإجراء عملية جراحية في عينيك، فتأكد من إبالغ طبيب العيون المعالج بأنك تتناول هذا الدواء. هذا ألنه<br />أثناء إجراء عملية إعتام عدسة العين على العين بسبب تعكر العدسة:<br />&bull;قد ال يزيد حجم البؤبؤ (الدائرة السوداء في منتصف عينك) حسب الحاجة<br />&bull;وقد تصبح القزحية (الجزء الملون من العين) رخوة أثناء الجراحة، ما قد يتسبب في إصابة العين باألضرار.<br />األطفال والمراهقون<br />لا تستخدم هذا الدواء مع الأطفال والمراهقين دون سن18. فمن غير المعروف ما إذا كان آمنًا وفعالا ً مع هاؤلاء المرضى.</p><p dir="RTL"><strong>الأدوية األخرى وبيانلي</strong><br />يُرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.<br />تلقي هذا الدواء مع دواء كاربامازيبين (دواء مضاد للصرع ومثبت للمزاج) قد يحتاج إلى تغيير جرعتك من هذا الدواء.<br />نظرًا إلى أن هذا الدواء يعمل في المقام الأول في الدماغ،فإن التداخل مع الأدوية الأخرى التي تعمل في الدماغ مثل الأدوية<br />النفسية الأخرى، والمواد الأفيونية، ومضادات الهيستامين، والأدوية المنوِّمة يمكن أن يسبب تفاقم الآثار الجانبية مثل<br />النعاس أو غيره من الآثار الجانبية على الدماغ.<br />أخبر طبيبك إذا كنت تتناول هذا الدواء أثناء تناول ريسبيريدون أو باليبيريدون عن طريق الفم لفترات طويلة من الزمن. قد<br />تحتاج إلى تغيير جرعتك من بيانلي.<br />بما أن هذاالدواء قد يتسبب في خفض ضغط الدم، يجب توخي الحذر عند استخدام هذا الدواء مع الأدوية الأخرى التي تعمل<br />على خفض ضغط الدم.<br />ويمكن أن يقلل هذا الدواء من تأثير الأدوية التي تُعالج مرض باركنسون ومتلازمة تململ الساقين (على سبيل المثال،<br />الليفودوبا).<br />قد يتسبب هذا الدواء في ظهور الرسم الكهربي للقلب (ECG)بشكل غير طبيعي، حيث تستغرق النبضة الكهربائية مدة<br />طويلة لكي تنتقل خلال جزء معين في القلب (يُعرف أيضًا باسم &quot;إطالة فترةQT.)&quot;تشمل الأدوية الأخرى التي لديها هذا<br />التأثير بعض الأدوية المستخدمة في علاج عدم انتظام ضربات القلب أو علاج العدوى، با لإضافة إلى األدوية المضادة<br />للذهان األخرى.<br />إذا كان لديك تاريخ لإلصابة بنوباتالصرع، فقد يزيد هذا الدواء خطر تعرضك لها. تشمل الأدوية األخرى التي لديها هذا<br />التأثير بعض الأدوية المستخدمة في علاج الإكتئاب أو عالج العدوى، بالإضافة إلى الأدوية المضادة للذهان األخرى.<br />يجب استخدام بيانلي بحذر مع الأدوية التي تزيد من نشاط الجهاز العصبي المركزي (المنشطات النفسية مثل ميثيل<br />الفينيدات).<br /><strong>بيانلي مع الكحول</strong><br />يحظر شرب الكحول.<br /><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كنت ِّ حامال ً أو ترضعين طفلك رضاعة طبيعية، أو كنت تعتقدين أنك حامل، أو تعتزمين أن تحملي، فالتمسي النصيحة<br />من الطبيب أو الصيدلي قبل تناول هذا الدواء.<br /><em>السيدات القادرات على الإنجاب</em><br />من المتوقع أن تبقى جرعة واحدة من هذا الدواء داخل الجسم لمدة تصل إلى4سنوات، ما قد يمثل خطرًا على الطفل. لذلك،<br />ينبغي عدم استخدام بيانلي مع النساء اللواتي يخططن لإنجاب طفل إلا إذا لزم الأمر بشكل واضح.<br /><em>الحَمْل</em><br />يجب ألا تستخدمي هذا الدواء أثناء الحمل ما لم تتم مناقشة ذلك مع طبيبكِّ. وقد تحدث الأعراض التالية لدى الأطفال حديثي<br />الوالدة الأمهات استخدمن الباليبيريدون في الثلث الأخير من الحمل (الأشهر الثالثة الأخيرة من حملهن): رعشة، وتصلب<br />العضالت و/أو ضعفها، والنعاس، والهياج، ومشكالت في التنفس، وصعوبة في الرضاعة. ينبغي مراقبة المواليد الجدد<br />بعناية وإذا ظهرت أي من هذه الأعراض على طفلك، فاطلب الرعاية الطبية لطفلك.<br /><em>الرضاعة الطبيعية</em><br />يمكن أن ينتقل هذا الدواء من الألم إلى الطفل عبرحليب/لبن الأم. قد يضر الطفل، حتى بعد وقت طويل من آخر جرعة.<br />لذلك، ينبغي عليك الامتناع عن الرضاعة الطبيعية إذا كنت تستخدمين هذا الدواء أو إذا استخدمته في السنوات الأربع<br />الماضية.<br /><br /><strong>القيادة واستخدام اآلالت</strong><br />قد يحدث دوار، وشعور بتعب شديد، ومشكلات في الرؤية أثناء العلاج باستخدام هذا الدواء (انظر القسم4). يجب مراعاة<br />ذلك في الحالات التي تتطلب يقظة كاملة، على سبيل المثال، عند قيادة سيارة أو التعامل مع اآلالت.<br /><strong>يحتوي بيانلي على الصوديوم</strong><br />يحتوي هذا الدواء على أقل من1ملليمول صوديوم (23ملغم) لكل جرعة؛ أي إن هذا الدواء يُعد &quot;خاليًا من الصوديوم&quot; في<br />الأساس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعطى لك هذا الدواء من قِّبل طبيبك أو أخصائي رعاية صحية آخر. سيخبرك الطبيب متى تحتاج حقنتك التالية. من المهم<br />عدم تفويت موعد جرعتك المقرَر. إذا لم تستطع الحفاظ على موعدك، فاحرص على الإتصال على الفور لتحديد موعد آخر<br />في أقرب وقت ممكن.<br />ستتلقى حقنة بيانلي في الأرداف مرة واحدة كل6أشهر.<br />وفقًا لما ستبديه من أعراض، فإن طبيبك قد يزيد أو يخفض كمية الدواء التي تتلقاها في الموعد المقرر لحقنتك التالية.<br /><u>المرضى الذين يعانون من مشاكل في الكلى</u><br />إذا كنت تعاني من مشكلات بسيطة في الكلى، فسيحدد الطبيب ما إذا كان بيانلي مالائمًا بناء ًا على الجرعة التي تتلقاها شهريًا<br />أو كل3أشهر من باليبيريدون بالمتات القابل للحقن. لا ينصح بجرعة1000مجم من بيانلي.<br />أما إذا كانت مشكلات الكلى لديك متوسطة أو شديدة، فلا يجب استخدام هذا الدواء.<br /><u>كبار السن</u><br />قد يعدل طبيبك الجرعة التي تحصل عليها من هذا الدواء في حالة تدهور وظائف الكلى<br /><strong>إذا أعطيت بيانلي بكميةأكبرمن اللازم</strong><br />سيتم إعطاؤك هذا الدواء تحت إشراف طبي، لذا من غير المحتمل أن يتم إعطاؤك جرعة أكبر من اللازم.<br />قد يتعرض المرضى الذين تم إعطاؤهم جرعة أكبرمن الباليبيريدون للأعراض التالية: النعاس أو السكون أو ضربات<br />القلب السريعة أو انخفاض ضغط الدم أو ظهور الرسم الكهربي (التتبع الكهربي) للقلب بشكل غير طبيعي أو حدوث<br />حركات بطيئة أو غير طبيعية في الوجه أو الجسم أو الذراعين أو الساقين.<br /><strong>إذا توقفت عن استخدام بيانلي</strong><br />إذا توقفت عن أخذ الحقن، فقد تتفاقم أعراض الفصام لديك. يجب عدم التوقف عن استخدام هذا الدواء إلا بطلب من طبيبك.<br />إذا كان لديك المزيد من الأسئلة بشأن استعمال هذا الدواء، فتوجه بها إلى الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم إصابة الجميع بها.<br /><strong>الاثار الجانبية الخطيرة</strong><br />إذا أصبت بأي من ألآلثار الجانبية الخطيرة التالية، فقد تحتاج إلى عالج طبي فوري. أبلغ طبيبك، أو اذهب إلى أقرب<br />مستشفى في الحال:<br />&bull;جلطات دموية في الأوردة وخاصة في الساقين. هذا أمر نادر (قد يؤثر في ما يصل إلى1من كل1000شخص).<br />تشمل األعراض:<br />oالتورم والألم والإحمرار في الساق-&quot;الخثار الوريدي العميق&quot;<br />oالألم في الصدر وصعوبة التنفس الناتجة عن جلطات دموية تنتقل عبر الأوعية الدموية إلى الرئتين-<br />&quot;انصمام رئوي&quot;.<br />&bull;عالمات السكتة الدماغية، التكرار غير معروف (لا يمكن تقدير مرات التكرار من البيانات المتوفرة). تشمل<br />الأعراض:<br /><br />oالتغيير المفاجئ في حالتك العقلية<br />oالضعف المفاجئ أو التخدير المفاجئ في الوجه والذراعين والأرجل وخصوصًا في جانب واحد، أو<br />صعوبة الكلام، حتى ولو لفترة زمنية قصيرة.<br />&bull;المتلازمة الخبيثة للدواء المضاد للذهان. هذا أمر نادر (قد يؤثر في ما يصل إلى1من كل1000شخص). تشمل<br />الأعراض:<br />oالحمى أو التصلب العضلي أو التعرق أو انخفاض مستوى الوعي.<br />&bull;الإنتصاب المطول الذي قد يكون مؤلمًا (قساح). هذا أمر نادر(قد يؤثر في ما يصل إلى1من كل1000شخص).<br />&bull;نفضان أو حركات إيقاعية ارتعاشية لا يمكنك بسببها التحكم في لسانك وفمك ووجهك أو أجزاء أخرى من جسمك<br />(خلل الحركة المتأخر). هذا أمر غير شائع (قد يؤثر في ما يصل إلى1من كل100شخص).<br />&bull;رد فعل تحسسي شديد (تفاعل تآقي)، التكرار غير معروف (لا يمكن تقديره من البيانات المتاحة). تشمل الأعراض:<br />oالحمى،<br />oتورم الفم أو الوجه أو الشفة أواللسان،<br />oضيق النفس،<br />oحكة وطفح جلدي وأحيانًا انخفاض في ضغط الدم.<br />وحتى إذا كنت قد تحملت مسبقًا تلقي الباليبيريدون أو الريسبيريدون عن طريق الفم، فنادرًاما تحدث ردود فعل تحسسية بعد<br />الحقن بباليبيريدون.<br />&bull;متالزمة القزحية المرنة، عندما تصبح القزحية (الجزء الملون من العين) مرنة أثناء جراحة إعتام عدسة العين. قد<br />يؤدي هذا إلى تلف العين (انظر أيضًا عمليات إعتام عدسة العين&quot; في القسم2). التكرار غير معروف (لايمكن<br />تقدير مرات التكرار من البيانات المتوفرة).<br />&bull;متلازمة ستيفنز جونسون أو انحلال البشرة النخري السمي. طفح جلدي شديد أو مهدد للحياة مصحوب ببثور وتقشر<br />جلدي قد يبدأ في الفم والأنف والعينين والأعضاء التناسلية وحولها وينتشر إلى مناطق أخرى من الجسم. التكرارات<br />غيرمعروفة (لا يمكن تقدير مرات التكرار من البيانات المتوفرة).<br />أخبر طبيبك على الفور أو اذهب إلى أقرب مستشفى فورًا إذا الحظت أيًا من&nbsp;الآثار الجانبية الخطيرة المذكورة سابقًا.<br />&bull;ندرة المحببات، انخفاض أعداد نوع معين بشكل خطير من كرات الدم البيضاءاللازمة لمكافحة العدوى في الدم.<br />تكرار هذا غير معروف (لا يمكن تقدير مرات التكرار من البيانات المتوفرة).<br /><strong>الآثار الجانبية األخرى</strong><br /><strong>آثار جانبية شائعة جدًا قد تؤثر في أكثر من1من كل10أشخاص</strong><br />&bull;صعوبة النوم أو الإستغراق فيه.<br /><strong>آثار جانبية شائعة: قد تؤثر في ما يصل إلى1من كل10أشخاص</strong><br />&bull;أعراض نزلات البرد الشائعة،عدوى في المسالك البولية، والشعور كأنك مصاب بلإنفلونزا.<br />&bull;يمكن أن يرفع بيانلي من مستويات هرمون &quot;البرولاكتين&quot; الموجود في عينة تحليل الدم (الذي قد يسبب أعراضًا أو<br />لا). عند ظهور أعراض ارتفاع البروالكتين، فقد تشمل: (لدى الذكور) تورم الثدي أو صعوبة في الإنتصاب أو<br />استمرار الإنتصاب أو خلل الوظائف الجنسيةالأخرى، (لدى الإناث) عدم الشعور براحة في الثدي أو انقطاع<br />الدورةالشهرية أو حدوث مشاكل أخرى في الدورة.<br />&bull;ارتفاع نسبة السكر في الدم، زيادة الوزن، فقدان الوزن، انخفاض الشهية.<br />&bull;الانفعالية، والاكتئاب، والتوتر.<br />&bull;الباركنسونية: قد تتضمن هذه الحالة بطء الحركة أو ضعفًا فيها، واإلحساس بتصلب العضلات أو تضامها (تجعل<br />الحركات متشنجة)، وأحيانًا حتى اإلحساس &quot;بتجمد&quot; في الحركة ثم البدء ثانية. تتضمن العلامات الأخرى<br />للباركنسونية البطء في تبديل خطوات المشي و/أو الرعشة في وقت الإسترخاء و/أو تزايد اللعاب و/أوسيلان<br />اللعاب، وفقدان التعبيرات على الوجه.<br />&bull;الشعوربعدم الراحةأو النعاس أو قلة االنتباه.<br />&bull;خلل التوترالعضلي: عبارة عن حالة مرضية مصحوبة بانقباض الإرادي بطيء أو مستمر في العضالت. في حين<br />أن خلل التوترالعضلي يمكن أن يصيب أي جزء من الجسم (وقد يؤدي إلى وضعية جسديةغير طبيعية)، غالبًا ما<br />يؤثر هذا المرض على عضلات الوجه مثل حدوث حركات غير طبيعية في العينين أو الفم أواللسان أوالفك.<br />&bull;الدوخة.<br />&bull;خلل الحركة: عبارة عن حالة مرضية مصحوبة بحركاتلاإرادية في العضلات، وقد تتضمن حركات متكررة أو<br />حركات تشنجية أو حركات توجع من الألم، أو النفضان.<br />&bull;الإرتجاف (الإرتعاش).<br /><br />&bull;الصداع.<br />&bull;سرعة معدل ضربات القلب.<br />&bull;ارتفاع ضغط الدم.<br />&bull;السعال، انسداد الأنف.<br />&bull;الالم في البطن، أو التقيؤ أو الشعور بالغثيان أو الإمساك أو الإسهال أو عسر الهضم أو ألم الأسنان.<br />&bull;زيادة إنزيمات ناقلات أمينات الكبد في الدم.<br />&bull;آلام العظام أو العضلات، آلام الظهر، آلام المفاصل.<br />&bull;انقطاع الدورات الشهرية.<br />&bull;الحمى، والضعف، والإعياء (الإرهاق).<br />&bull;إبداء رد فعل في موضع الحقن يتضمن الحكة أوالألم أو التورم.<br /><strong>آثار جانبية غير شائعة: قد تؤثر في ما يصل إلى1من كل100شخص</strong><br />&bull;الإلتهاب الرئوي، والعدوى في الصدر (التهاب الشعب الهوائية)،والعدوى في ممرات التنفس،والعدوى في<br />الجيوب الأنفية،والعدوى في المثانة،والعدوى في الأذن، والتهاب اللوزتين، والعدوى الفطرية في الأظافر،<br />والعدوى في الجلد.<br />&bull;انخفض عدد خلايا الدم البيضاء.<br />&bull;فقر الدم.<br />&bull;رد فعل تحسسي.<br />&bull;الإصابة بمرض السكري أو تفاقمه، وزيادة الأنسولين (هرمون يتحكم في مستويات السكر في الدم) في الدم.<br />&bull;زيادة الشهية.<br />&bull;فقدان الشهية الذي يؤدي إلى سوء التغذية وانخفاض وزن الجسم.<br />&bull;ارتفاع نسبة الدهون الثلاثية في الدم (نوع من أنواع دهون الدم)، زيادة الكوليسترول في الدم.<br />&bull;اضطراب النوم، والمزاج المتهيج (الهوس)، وانخفاض الرغبة الجنسية،والعصبية، والكوابيس.<br />&bull;الإغماء،الرغبة المستمرة في تحريك أجزاء الجسم، دوخة عند القيام، حدوث اضطراب في الإنتباه، مشاكل في<br />الكلام، ،فقدان أو تغير في حاسةالتذوق،انخفاض إحساس الجلد باأللم واللمس، اإلحساس بالتخدر أو الوخز أو<br />تنميل الجلد.<br />&bull;الرؤية الضبابية،والعدوى فيالعين أو &quot;العين القرنفلية&quot;، وجفاف العين.<br />&bull;اإلحساس بعدم االتزان (دوار) أو وجود طنين في األذنين أو ألم في األذن.<br />&bull;انقطاع التوصيل بين األجزاء العلوية والسفلية للقلب، وحدوث التوصيل الكهربي في القلب بشكل غير طبيعي،<br />وإطالة فترةQTفي القلب، وسرعة ضرباتالقلب عند الوقوف، وبطء معدل ضربات القلب، وحدوث التتبع<br />الكهربي للقلب (الرسم الكهربي للقلب أوECG)بشكل غير طبيعي، والشعور برفرفة أو ضربات عنيفة في صدرك<br />(خفقان القلب).<br />&bull;انخفاض ضغط الدم أو انخفاض ضغط الدم عند الوقوف (وبناء ًا على ذلك، قد يشعر بعض الأشخاص الذين يتناولون<br />هذا الدواء بالإغماء أو الدوخة أو قد يفقدون وعيهم عند الوقوف أوالنهوض فجأة).<br />&bull;ضيق في التنفس، ألم في الحلق، نزيف أنفي.<br />&bull;الشعوربعدم الراحةفي البطن،والعدوى في المعدة أو الأمعاء، وصعوبة في البلع، وجفاف الفم، ألإخراج المفرط<br />للغازات أو الرياح.<br />&bull;زيادةGGT(إنزيم كبدي يسمى ناقل جاما جلوتاميل) في الدم، زيادة إنزيمات الكبد في الدم.<br />&bull;الشرى (أو &quot;طفح القراص&quot;)، والحكة، والطفح الجلدي، وتساقط الشعر،و الإكزيما،وجفاف الجلد، واحمرار الجلد،<br />وحب الشباب، والتقيحات تحت الجلد، وإصابة فروة الرأس أو الجلد بقشور أو حكة.<br />&bull;زيادة إنزيمCPK(كرياتين فوسفوكيناز)، وهو إنزيم في دمك.<br />&bull;تشنجات العضلات، وتيبس المفاصل، وضعف العضلات.<br />&bull;سَلس (ضعف التحكم في) البول، التبول المتكرر، ووجود ألم عند التبول.<br />&bull;ضعف الإنتصاب، واضطراب في القذف، وانقطاع الدورةالشهرية أو حدوث مشكلات أخرى في الدورةلدي<br />الإناث، وبروز الصدر لدى الرجال، وخلل في الوظيفة الجنسية، وألم في الثدي وتسرب للحليب/اللبن من الثديين<br />&bull;تورم الوجه أو الفم أو العينين أو الشفتين، أو تورم الجسم أو الذراعين أو الساقين.<br />&bull;زيادة في درجة حرارة الجسم.<br />&bull;تغير في طريقة مشيتك.<br />&bull;آلام الصدر، عدم الشعوربارتياح في الصدر، الشعور بالتعب.<br />&bull;تصلب الجلد.<br />&bull;السقوط.<br /><br /><strong>آثار جانبية نادرة: قد تؤثر في ما يصل إلى1من كل1000شخص</strong><br />&bull;عدوى في العين.<br />&bull;التهاب الجلد الناجم عن العث.<br />&bull;زيادة في اليوزينيات (نوع من كرات الدم البيضاء) في الدم.<br />&bull;انخفاض في عدد الصفائح الدموية (خلايا الدم التي تساعدك على وقف النزيف).<br />&bull;إفراز غير ملائم للهرمون الذي يتحكم في كمية البول.<br />&bull;وجود سكر في البول.<br />&bull;المضاعفات المهددة للحياة الناتجة عن عدم انتظام معدلات السكري.<br />&bull;انخفاض السكر في الدم.<br />&bull;الإفراط في شرب المياه.<br />&bull;التشوش.<br />&bull;عدم الحركة أوالإستجابة أثناءاليقظة (الجامود).<br />&bull;المشي أثناء النوم.<br />&bull;فتور العاطفة.<br />&bull;عدم القدرة على الوصول إلى هزة الجماع.<br />&bull;عدمالإستجابة للمنبهات، فقدان الوعي، انخفاض مستوى الوعي، الإختلاجات (النوبات)، اضطراب التوازن.<br />&bull;عدم تناسق الحركة.<br />&bull;المياه الزرقاء (ارتفاع ضغط مقلة العين).<br />&bull;مشكلات في حركةالعين، ودوران العين، وفرط حساسية العينين للضوء، وزيادة الدموع، واحمرار العينين.<br />&bull;اهتزاز الرأس الذي لا يمكنك السيطرة عليه.<br />&bull;رجفان أذيني (ضربات قلب غير طبيعية)، عدم انتظام ضربات القلب.<br />&bull;الإحمرار.<br />&bull;صعوبة في التنفس أثناء النوم (انقطاع النفس أثناء النوم).<br />&bull;احتقان الرئة، احتقان ممرات التنفس.<br />&bull;أصوات طقطقة في الرئة.<br />&bull;الأزيز.<br />&bull;التهاب البنكرياس،<br />&bull;تورم اللسان،<br />&bull;سلس البراز، براز صلب جدًا، انسداد في الأمعاء.<br />&bull;تشقق الشفاه.<br />&bull;الطفح الجلدي المرتبط بالدواء، وسماكة الجلد، وقشرة الرأس.<br />&bull;تورم المفاصل.<br />&bull;تمزق في الأنسجة العضلية(&quot;انحلال الربيدات&quot;).<br />&bull;عدم القدرة على إخراج البول.<br />&bull;الشعور بانزعاج في الثدي، وتضخم الغدد الموجودة في الثديين، وتضخم الثدي.<br />&bull;الإفرازات المهبلية.<br />&bull;انخفاض درجة حرارة الجسم للغاية، والقشعريرة، والشعور بالعطش.<br />&bull;أعراض التوقف عن الدواء.<br />&bull;تجمع صديدي ناجم عن العدوى عند موضع الحقن،والعدوى الجلديةالعميقة، وحدوث تكيس في موضع الحقن،<br />ووجود كدمات في موضع الحقن.<br /><strong>غير معروفة: لا يمكن تقدير مرات التكرار من البيانات المتوفرة</strong><br />&bull;الإفراط في تناول الماء بشكل خطير.<br />&bull;اضطراب الأكل المرتبط بالنوم.<br />&bull;الغيبوبة الناتجة عن عدم انضباط معدلات السكري.<br />&bull;التنفس السريع والضحل، والإلتهاب الرئوي الناجم عن استنشاق الطعام، واضطراب الصوت.<br />&bull;انخفاض الأكسجين في أجزاء من الجسم (بسبب انخفاض تدفق الدم).<br />&bull;قلةحركة الأمعاء التي تسبب االنسداد.<br />&bull;اصفرار الجلد والعينين (اليرقان).<br />&bull;تغير لون الجلد.<br />&bull;وضعية جسدية غير طبيعية.<br />&bull;قد يعاني الأطفال حديثي الولادة لأمهات تناولن بيانلي أثناء الحمل من آثار جانبية للدواء و/أو أعراض انسحاب،<br />مثل الإنفعالية، وتقلصات العضلات البطيئة أو المستمرة، والإرتعاش، والنعاس، ومشكلات في التنفس أو التغذية.<br />&bull;انخفاض في درجة حرارة الجسم.<br />&bull;موت خلايا الجلد في موضع الحقن، وقرحة في موضع الحقن.<br /><strong>الإبلاغ عنالآثار الجانبية</strong><br />إذا تعرضت ألي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه<br />النشرة. من خلالالإبلاغ عن اآلثار الجانبية، يمكن أن تساعد على توفير مزيد من المعلومات حول أمان هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول األطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصالحية المحدد على العبوة الكرتونية. يشير تاريخ انتهاء الصالحية إلى آخر يوم<br />من ذلك الشهر.<br /><strong>يمنع التخزين في درجة حرارة أعلى من30درجة مئوية.</strong><br />الشحن والتخزين في وضع أفقي. انظر الأسهم على عبوة المنتج لمعرفة التوجيه الصحيح.<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من<br />الأدوية التي لم تعد بحاجة إلى استخدامها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات بيانلي</strong></p><p dir="RTL">المادة الفعالة هي الباليبيريدون.<br />تحتوي كل محقنة بيانلي700مجم معبأة مسبقًا على1092مجم بالبيبيريدون بالميتات، ما يعادل700مجم بالبيبيريدونفي<br />3.5مل.<br />تحتوي كل محقنة بيانلي1000مجم معبأة مسبقًا على1560مجم بالبيبيريدون بالميتات، ما يعادل1000مجم بالبيبيريدون<br />في5مل.<br />المكوناتالأخرى هي:<br />بوليسوربات20<br />جليكول بولي إيثيلين4000<br />حمض الستريك أحادي الماء<br />فوسفات ثنائي هيدروجين الصوديوم أحادي الإماهة<br />هيدروكسيد الصوديوم (لمعادلة درجة الحموضة)<br />ماء للحقن</p><p dir="RTL"><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بيانلي ومحتويات العبوة</strong></p><p dir="RTL">بيانلي هومعلَّق أبيض مائل إلى اللون العاجي ممتد المفعول للحقن في محقنة معبأة مسبقًا. درجة الحموضة حالي7.0.<br />سيقوم الطبيب أو الممرضة بهز المحقنة بسرعة كبيرةلإعادة المزج قبل إعطائها كحقنة.<br />تحتوي كل عبوة على محقنةواحدة (1) معبأة مسبقًا وإبرةواحدة.<br />قد لا تتوفر العبوات من جميع الأحجام والتركيزات بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل الرخصة التسويقية</strong><br />جانسن سيلاج انترناشونال إن في ترنهوتسويج-30-بي-2340بيرس-بلجيكا<br /><br /><strong>الشركة المصنّعة</strong></p><p dir="RTL">جانسن فارماسيوتيكا إن في،&nbsp;ترنهوتسويج- 30 -بي- 2340&nbsp;بلجيكا -بيرس</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر مراجعةلهذه النشرة في25مايو 2023.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BYANNLI 700 mg prolonged-release suspension for injection in pre-filled syringe 
BYANNLI 1 000 mg prolonged-release suspension for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                700 mg prolonged release suspension for injection

Each pre filled syringe contains 1 092 mg paliperidone palmitate equivalent to 700 mg paliperidone

1 000 mg prolonged release suspension for injection

Each pre filled syringe contains 1 560 mg paliperidone palmitate equivalent to 1 000 mg paliperidone

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release suspension for injection (injection).
The suspension is white to off-white. The suspension is pH neutral (approximately 7.0).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BYANNLI, a 6-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Patients who are adequately treated with 1-monthly paliperidone palmitate injection at doses of</p><p>100 mg or 150 mg (preferably for four months or more) or 3-monthly paliperidone palmitate injection at doses of 350 mg or 525 mg (for at least one injection cycle) and do not require dose adjustment may be transitioned to 6-monthly paliperidone palmitate injection.</p><p>&nbsp;</p><p><em>BYANNLI for patients adequately treated with 1-monthly paliperidone palmitate injection</em></p><p>BYANNLI should be initiated in place of the next scheduled dose of 1-monthly paliperidone palmitate injection (&plusmn; 7 days). To establish a consistent maintenance dose, it is recommended that the last two doses of 1-monthly paliperidone palmitate injection be the same dose strength before starting BYANNLI. The BYANNLI dose should be based on the previous 1-monthly paliperidone palmitate injectable dose shown in the following table:</p><p>&nbsp;</p><p>Transitioning to BYANNLI for patients adequately treated with 1-monthly paliperidone palmitate injection</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>If the last dose of 1-monthly paliperidone injection is</p></td><td style="vertical-align:top"><p>Initiate BYANNLI at the following dose<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>700 mg</p></td></tr><tr><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>1 000 mg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span lang=EN-US
style='font-size:1.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='width:453.7pt;height:.5pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9074,10">
 <v:rect id="_x0000_s1027" style='position:absolute;width:9074;height:10'
  fillcolor="black" stroked="f"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="605" height="1" src="file:///C:\Users\halima\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US style='font-size:1.0pt;mso-bidi-font-size:11.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:453.7pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no equivalent doses of BYANNLI for the 25 mg, 50 mg or 75 mg doses of 1-monthly paliperidone palmitate injection, which were not studied.</p><p>&nbsp;</p><p><em>BYANNLI for patients adequately treated with 3-monthly paliperidone palmitate injection</em></p><p>BYANNLI should be initiated in place of the next scheduled dose of 3-monthly paliperidone palmitate injection (&plusmn; 14 days). The BYANNLI dose should be based on the previous 3-monthly paliperidone palmitate injectable dose shown in the following table:</p><p>&nbsp;</p><p>Transitioning to BYANNLI for patients adequately treated with 3-monthly paliperidone palmitate injection</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>If the last dose of 3-monthly paliperidone injection is</p></td><td style="vertical-align:top"><p>Initiate BYANNLI at the following dose<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>350 mg</p></td><td style="vertical-align:top"><p>700 mg</p></td></tr><tr><td style="vertical-align:top"><p>525 mg</p></td><td style="vertical-align:top"><p>1 000 mg</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no equivalent doses of BYANNLI for the 175 mg or 263 mg doses of 3-monthly paliperidone palmitate injection, which were not studied.</p><p>&nbsp;</p><p>Following the initial BYANNLI dose, BYANNLI should be administered once every 6 months. If necessary, patients may be given the injection up to 2 weeks before or up to 3 weeks after the 6-month scheduled timepoint (see also <em>Missed dose </em>section).</p><p>&nbsp;</p><p>If needed, dose adjustment of BYANNLI can be made every 6 months between the dose levels of 700 mg and 1 000 mg based on individual patient tolerability and/or efficacy. Due to the long-acting</p><p>nature of BYANNLI the patient&rsquo;s response to an adjusted dose may not be apparent for several months (see section 5.2). If the patient remains symptomatic, they should be managed according to clinical practice.</p><p>&nbsp;</p><p><em>Switching from other antipsychotic medicinal products</em></p><p>Patients should not be switched directly from other antipsychotics as BYANNLI should only be initiated after the patient is stabilised on 3-monthly or 1-monthly paliperidone palmitate injectable products.</p><p>&nbsp;</p><p><em>Switching from BYANNLI to other antipsychotic medicinal products</em></p><p>If BYANNLI is discontinued, its prolonged-release characteristics must be considered.</p><p>&nbsp;</p><p><em>Transitioning from BYANNLI to 1-monthly paliperidone palmitate injection</em></p><p>When transitioning from BYANNLI to 1-monthly paliperidone palmitate injection, the 1-monthly injection should be administered at the time of the next scheduled BYANNLI dose as shown in the following table. The initiation dosing as described in the prescribing information for 1-monthly paliperidone palmitate injection is not required. The 1-monthly paliperidone palmitate injection should then be dosed at monthly intervals as described within the prescribing information for that product.</p><p>&nbsp;</p><p>Doses of 1-monthly paliperidone palmitate injectable for patients transitioning from BYANNLI</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>If the last dose of BYANNLI is</p></td><td style="vertical-align:top"><p>Initiate 1-monthly paliperidone injection 6 months later at the following dose</p></td></tr><tr><td style="vertical-align:top"><p>700 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td></tr><tr><td style="vertical-align:top"><p>1 000 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Transitioning from BYANNLI to 3-monthly paliperidone palmitate injectable</em></p><p>When transitioning patients from BYANNLI to 3-monthly paliperidone palmitate injection, the 3-monthly injection should be administered at the time of the next scheduled BYANNLI dose as</p><p>shown in the following table. The initiation dosing regimen described in the prescribing information for 3-monthly paliperidone palmitate injection is not required. The 3-monthly paliperidone palmitate injection should then be dosed at 3-monthly intervals as described within the prescribing information for that product.</p><p>&nbsp;</p><p>Doses of 3-monthly paliperidone palmitate injectable for patients transitioning from BYANNLI</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>If the last dose of BYANNLI is</p></td><td style="vertical-align:top"><p>Initiate 3-monthly paliperidone injectable 6 months later at the following dose</p></td></tr><tr><td style="vertical-align:top"><p>700 mg</p></td><td style="vertical-align:top"><p>350 mg</p></td></tr><tr><td style="vertical-align:top"><p>1 000 mg</p></td><td style="vertical-align:top"><p>525 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Transitioning from BYANNLI to oral daily paliperidone prolonged-release tablets</em></p><p>When transitioning patients from BYANNLI to paliperidone prolonged-release tablets, the daily dosing of paliperidone prolonged-release tablets should be started 6 months after the last BYANNLI dose and treatment should be continued with paliperidone prolonged-release tablets as described in the table below. Patients previously stabilised on different doses of BYANNLI can attain similar paliperidone exposure with paliperidone prolonged-release tablets according to the following conversion regimens:</p><p>&nbsp;</p><p>Doses of paliperidone prolonged-release tablets for patients transitioning from BYANNLI*</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>If the last dose of BYANNLI is</p></td><td colspan="3" style="vertical-align:top"><p>Months after last BYANNLI dose</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 9 months</p></td><td style="vertical-align:top"><p>More than 9 months to 12 months</p></td><td style="vertical-align:top"><p>More than 12 months</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Daily dose of paliperidone prolonged-release tablets</p></td></tr><tr><td style="vertical-align:top"><p>700 mg</p></td><td style="vertical-align:top"><p>3 mg</p></td><td style="vertical-align:top"><p>6 mg</p></td><td style="vertical-align:top"><p>9 mg</p></td></tr><tr><td style="vertical-align:top"><p>1 000 mg</p></td><td style="vertical-align:top"><p>6 mg</p></td><td style="vertical-align:top"><p>9 mg</p></td><td style="vertical-align:top"><p>12 mg</p></td></tr></tbody></table><p>* All doses of once daily paliperidone prolonged-release tablets should be individualised to the specific patient, taking into consideration variables such as reasons for transitioning, response to previous paliperidone treatment, severity of psychotic symptoms, and/or propensity for side effects.</p><p>&nbsp;</p><p><u>Missed dose</u></p><p>&nbsp;</p><p><em>Dosing window</em></p><p>BYANNLI should be injected once every 6 months. To avoid a missed dose of BYANNLI, patients may be given the injection up to 2 weeks before or up to 3 weeks after the scheduled 6-month time point.</p><p>&nbsp;</p><p>Missed doses</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>If scheduled dose is missed and the time since last injection is</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>up to 6 months and 3 weeks</p></td><td style="vertical-align:top"><p>The injection of BYANNLI should be administered as soon as possible and then</p><p>resume the 6-monthly injection schedule.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 6 months and 3 weeks up to &lt; 8 months</p></td><td style="vertical-align:top"><p>The injection of BYANNLI should not be administered. Use the recommended re-initiation</p><p>regimen with 1-monthly paliperidone palmitate injectable as shown in the table below.</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 8 months to &le; 11 months</p></td><td style="vertical-align:top"><p>The injection of BYANNLI should not be administered. Use the recommended re-initiation</p><p>regimen with 1-monthly paliperidone palmitate injectable as shown in the table below.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 11 months</p></td><td style="vertical-align:top"><p>The injection of BYANNLI should not be administered. Re-initiate treatment with</p><p>1-monthly paliperidone palmitate injectable as described in the prescribing information for that product. BYANNLI can then be resumed after the patient has been adequately treated with</p><p>1-monthly paliperidone palmitate injectable, preferably for four months or more.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Recommended re-initiation regimen after missing &gt; 6 months and 3 weeks up to &lt; 8 months of BYANNLI</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>If the last dose of BYANNLI was</p></td><td style="vertical-align:top"><p>Administer 1-monthly paliperidone palmitate injectable (into deltoida muscle)</p></td><td style="vertical-align:top"><p>Then administer BYANNLI (into gluteal muscle)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>1 month after Day 1</p></td></tr><tr><td style="vertical-align:top"><p>700 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>700 mg</p></td></tr><tr><td style="vertical-align:top"><p>1 000 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td><td style="vertical-align:top"><p>1 000 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Recommended re-initiation regimen after missing </strong>&ge; <strong>8 months to </strong>&le; <strong>11 months of BYANNLI</strong></p></td></tr><tr><td style="vertical-align:top"><p>If the last dose of BYANNLI was</p></td><td colspan="2" style="vertical-align:top"><p>Administer 1-monthly paliperidone palmitate injectable (into deltoid<sup>a</sup> muscle)</p></td><td style="vertical-align:top"><p>Then administer</p><p>BYANNLI (into gluteal muscle)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>1 month after Day 8</p></td></tr><tr><td style="vertical-align:top"><p>700 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>700 mg</p></td></tr><tr><td style="vertical-align:top"><p>1 000 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>1 000 mg</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See <em>Information intended for healthcare professionals </em>for the 1-monthly paliperidone palmitate injectable product for deltoid injection needle selection based on body weight.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>Efficacy and safety in elderly &gt; 65 years have not been established.</p><p>&nbsp;</p><p>In general, recommended dosing of BYANNLI for elderly patients with normal renal function is the same as for younger adult patients with normal renal function. As elderly patients may have reduced renal function, see <em>Renal impairment </em>below for dosing recommendations in patients with renal impairment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>While BYANNLI has not been systematically studied in patients with renal impairment, the plasma concentrations of orally administered paliperidone are increased in these patients (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>Patients with mild renal impairment (creatinine clearance &ge; 50 to &le; 80 mL/min) who are stabilised on either 100 mg 1-monthly paliperidone palmitate injectable or 350 mg 3-monthly paliperidone palmitate injectable can be transitioned to BYANNLI at the 700 mg dose only. The 1 000 mg dose of BYANNLI is not recommended for patients with mild renal impairment.</p><p>&nbsp;</p><p>BYANNLI is not recommended in patients with moderate or severe renal impairment (creatinine clearance &lt; 50 mL/min).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>BYANNLI has not been studied in patients with hepatic impairment. Based on experience with oral paliperidone, no dose adjustment is required in patients with mild or moderate hepatic impairment. As paliperidone has not been studied in patients with severe hepatic impairment, caution is recommended in such patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of BYANNLI in children and adolescents &lt; 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>BYANNLI is for gluteal intramuscular use only. It must not be administered by any other route. Each injection must be administered only by a healthcare professional giving the full dose in a single injection. It should be injected slowly, deep into the upper-outer quadrant of the gluteal muscle. A switch between the two gluteal muscles should be considered for future injections in the event of injection site discomfort (see section 4.8).</p><p>&nbsp;</p><p>The needle for administration of BYANNLI is a thin wall 1&frac12; inch, 20 gauge (0.9 mm &times; 38 mm) needle, regardless of body weight. BYANNLI must be administered using only the thin wall needle that is provided in the BYANNLI pack. Needles from the 3-monthly or 1-monthly paliperidone palmitate injectable pack or other commercially available needles must not be used when administering BYANNLI (see <em>Information intended for healthcare professionals</em>).</p><p>&nbsp;</p><p>The contents of the pre-filled syringe should be inspected visually for foreign matter and discolouration prior to administration. This highly concentrated product requires specific steps to ensure complete resuspension.</p><p>&nbsp;</p><p>It is important to <strong>shake the syringe with the syringe tip cap pointing up </strong>using a <strong>very fast </strong>up and down motion with a loose wrist <strong>for at least 15 seconds. Rest briefly, then shake again </strong>in the same way, using a <strong>very fast </strong>up and down motion with a loose wrist for a <strong>further 15 seconds </strong>to resuspend the medicinal product. <strong>Proceed immediately to inject BYANNLI</strong>. If more than five minutes passes before the injection is administered, shake the syringe again, as above to resuspend the medicinal product (see <em>Information intended for healthcare professionals</em>).</p><p>&nbsp;</p><p><em>Incomplete administration</em></p><p>BYANNLI is a highly concentrated product that requires specific steps to ensure complete resuspension and prevent clogging of the needle during injection. Proper shaking can reduce the likelihood of an incomplete injection. Shipping and storing the carton in a horizontal orientation improves the ability to resuspend this highly concentrated product. Follow the details in the <em>Information intended for healthcare professionals </em>to avoid an incomplete injection.</p><p>&nbsp;</p><p>However, in the event of an incompletely injected dose, the dose remaining in the syringe should not be re-injected and another dose should not be given since it is difficult to estimate the proportion of the dose actually administered. The patient should be closely monitored and managed as clinically appropriate until the next scheduled 6-monthly injection of BYANNLI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to risperidone or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in patients who are in an acutely agitated or severely psychotic state</u></p><p>&nbsp;</p><p>BYANNLI should not be used to manage acutely agitated or severely psychotic states when immediate symptom control is warranted.</p><p>&nbsp;</p><p><u>QT interval</u></p><p>&nbsp;</p><p>Caution should be exercised when paliperidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other medicinal products thought to prolong the QT interval.</p><p>&nbsp;</p><p><u>Neuroleptic malignant syndrome (NMS)</u></p><p>&nbsp;</p><p>NMS, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness, and elevated serum creatine phosphokinase levels has been reported to occur with paliperidone.</p><p>Additional clinical signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs or symptoms indicative of NMS, paliperidone should be discontinued.</p><p>Consideration should be given to the long-acting nature of BYANNLI. <u>Tardive dyskinesia/extrapyramidal symptoms</u></p><p>Medicinal products with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical, involuntary movements, predominantly of the tongue and/or face. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics, including paliperidone, should be considered. Consideration should be given to the long-acting nature of BYANNLI.</p><p>&nbsp;</p><p>Caution is warranted in patients receiving both, psychostimulants (e.g., methylphenidate) and paliperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medicinal products. Gradual withdrawal of stimulant treatment is recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Leucopenia, neutropenia, and agranulocytosis</u></p><p>&nbsp;</p><p>Events of leucopenia, neutropenia, and agranulocytosis have been reported with paliperidone. Patients with a history of a clinically significant low white blood cell (WBC) count or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of BYANNLI should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count</p><p>&lt; 1 &times; 10<sup>9</sup>/L) should discontinue BYANNLI and have their WBC followed until recovery. Consideration should be given to the long-acting nature of BYANNLI.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Hypersensitivity reactions can occur even in patients who have previously tolerated oral risperidone or oral paliperidone (see section 4.8).</p><p>&nbsp;</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>&nbsp;</p><p>Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes, including diabetic coma and ketoacidosis, have been reported with paliperidone. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with BYANNLI should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><u>Body weight change</u></p><p>&nbsp;</p><p>Significant weight change has been reported with BYANNLI use. Weight should be monitored regularly (see section 4.8)<em>.</em></p><p><em>&nbsp;</em></p><p><u>Use in patients with prolactin-dependent tumours</u></p><p>&nbsp;</p><p>Tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history. Paliperidone should be used with caution in patients with a pre-existing tumour that may be prolactin-dependent.</p><p>&nbsp;</p><p><u>Orthostatic hypotension</u></p><p>&nbsp;</p><p>Paliperidone may induce orthostatic hypotension in some patients based on its alpha-adrenergic blocking activity. BYANNLI should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction or ischaemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration and hypovolaemia).</p><p>&nbsp;</p><p><u>Seizures</u></p><p>&nbsp;</p><p>BYANNLI should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>The plasma concentrations of paliperidone are increased in patients with renal impairment. Patients with mild renal impairment (creatinine clearance &ge; 50 mL/min to &le; 80 mL/min) who are stabilised on either 1-monthly paliperidone palmitate injectable or 3-monthly paliperidone palmitate injectable may be transitioned to BYANNLI (see section 4.2). The 1 000 mg dose of BYANNLI is not recommended for patients with mild renal impairment. BYANNLI is not recommended in patients with moderate or severe renal impairment (creatinine clearance &lt; 50 mL/min) (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>No data are available in patients with severe hepatic impairment (Child-Pugh class C). Caution is recommended if paliperidone is used in such patients.</p><p>&nbsp;</p><p><u>Elderly patients with dementia</u></p><p>&nbsp;</p><p>BYANNLI has not been studied in elderly patients with dementia. BYANNLI is not recommended to treat elderly patients with dementia due to increased risk of overall mortality and cerebrovascular adverse reactions.</p><p>&nbsp;</p><p>The experience from risperidone cited below is considered valid also for paliperidone.</p><p>&nbsp;</p><p><em>Overall mortality</em></p><p>In a meta-analysis of 17 controlled clinical trials, elderly patients with dementia treated with other atypical antipsychotics, including risperidone, aripiprazole, olanzapine, and quetiapine had an increased risk of mortality compared to placebo. Among those treated with risperidone, the mortality was 4% compared with 3.1% for placebo.</p><p>&nbsp;</p><p><em>Cerebrovascular adverse reactions</em></p><p>An approximately 3-fold increased risk of cerebrovascular adverse reactions has been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole, and olanzapine. The mechanism for this increased risk is not known.</p><p>&nbsp;</p><p><u>Parkinson&rsquo;s disease and dementia with Lewy bodies (DLB)</u></p><p>&nbsp;</p><p>Physicians should weigh the risks versus the benefits when prescribing BYANNLI to patients with Parkinson&rsquo;s disease or DLB since both groups may be at increased risk of NMS as well as having an increased sensitivity to antipsychotics. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms.</p><p>&nbsp;</p><p><u>Priapism</u></p><p>&nbsp;</p><p>Antipsychotic medicinal products (including paliperidone) with alpha-adrenergic blocking effects have been reported to induce priapism. Patients should be informed to seek urgent medical care in case that priapism has not been resolved within 4 hours.</p><p>&nbsp;</p><p><u>Body temperature regulation</u></p><p>&nbsp;</p><p>Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic medicinal products. Appropriate care is advised when prescribing BYANNLI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medicinal products with anticholinergic activity or being subject to dehydration.</p><p>&nbsp;</p><p><u>Venous thromboembolism (VTE)</u></p><p>&nbsp;</p><p>Cases of VTE have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with BYANNLI and preventative measures undertaken.</p><p>&nbsp;</p><p><u>Antiemetic effect</u></p><p>&nbsp;</p><p>An antiemetic effect was observed in preclinical studies with paliperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdose with certain medicinal products or of conditions such as intestinal obstruction, Reye&rsquo;s syndrome and brain tumour.</p><p>&nbsp;</p><p><u>Administration</u></p><p>&nbsp;</p><p>Care must be taken to avoid inadvertent injection of BYANNLI into a blood vessel. <u>Intraoperative floppy iris syndrome (IFIS)</u></p><p>IFIS has been observed during cataract surgery in patients treated with medicinal products with alpha 1a-adrenergic antagonist effect, such as BYANNLI (see section 4.8).</p><p>&nbsp;</p><p>IFIS may increase the risk of eye complications during and after the operation. Current or past use of medicinal products with alpha 1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery. The potential benefit of stopping alpha 1 blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially sodium-free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution is advised when prescribing BYANNLI with medicinal products known to prolong the QT interval, e.g., class IA antiarrhythmics (e.g., quinidine, disopyramide) and class III antiarrhythmics (e.g., amiodarone, sotalol), some antihistaminics, some antibiotics (e.g., fluoroquinolones), some other antipsychotics and some antimalarials (e.g., mefloquine). This list is indicative and not exhaustive.</p><p>&nbsp;</p><p><u>Potential for BYANNLI to affect other medicines</u></p><p>&nbsp;</p><p>Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicinal products that are metabolised by cytochrome P450 isozymes.</p><p>&nbsp;</p><p>Given the primary central nervous system (CNS) effects of paliperidone (see section 4.8), BYANNLI should be used with caution in combination with other centrally acting medicinal products, e.g., anxiolytics, most antipsychotics, hypnotics, opiates, etc. or alcohol.</p><p>&nbsp;</p><p>Paliperidone may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end-stage Parkinson&rsquo;s disease, the lowest effective dose of each treatment should be prescribed.</p><p>&nbsp;</p><p>Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when BYANNLI is administered with other medicinal products that have this potential, e.g., other antipsychotics, tricyclics.</p><p>&nbsp;</p><p>Caution is advised if paliperidone is combined with other medicinal products known to lower the seizure threshold (i.e., phenothiazines or butyrophenones, tricyclics or SSRIs, tramadol, mefloquine, etc.).</p><p>&nbsp;</p><p>Co-administration of oral paliperidone prolonged-release tablets at steady-state (12 mg once daily) with divalproex sodium prolonged-release tablets (500 mg to 2 000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.</p><p>&nbsp;</p><p>No interaction study between BYANNLI and lithium has been performed, however, a pharmacokinetic interaction is not likely to occur.</p><p>&nbsp;</p><p><u>Potential for other medicines to affect BYANNLI</u></p><p>&nbsp;</p><p><em>In vitro </em>studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, but there are no indications <em>in vitro </em>nor <em>in vivo </em>that these isozymes play a significant role in the metabolism of paliperidone. Concomitant administration of oral paliperidone with paroxetine, a potent CYP2D6 inhibitor, showed no clinically significant effect on the pharmacokinetics of paliperidone.</p><p>&nbsp;</p><p>Co-administration of oral paliperidone prolonged-release once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone likely as a result of induction of renal P-gp by carbamazepine. A minor decrease in the amount of active substance excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. Larger decreases in plasma concentrations of paliperidone could occur with higher doses of carbamazepine.</p><p>On initiation of carbamazepine, the dose of BYANNLI should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of BYANNLI should be</p><p>re-evaluated and decreased if necessary. Consideration should be given to the long-acting nature of BYANNLI.</p><p>&nbsp;</p><p>Co-administration of a single dose of an oral paliperidone prolonged-release tablet 12 mg with divalproex sodium prolonged-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone, likely as a result of increased oral absorption. Since no effect on the systemic clearance was observed, a clinically significant interaction would not be expected between divalproex sodium prolonged-release tablets and BYANNLI gluteal intramuscular injection. This interaction has not been studied with BYANNLI.</p><p>&nbsp;</p><p><u>Concomitant use of BYANNLI with risperidone or oral paliperidone</u></p><p>&nbsp;</p><p>Since paliperidone is the major active metabolite of risperidone, caution should be exercised when BYANNLI is co-administered with risperidone or with oral paliperidone for extended periods of time. Safety data involving concomitant use of BYANNLI with other antipsychotics is limited.</p><p>&nbsp;</p><p><u>Concomitant use of BYANNLI with psychostimulants</u></p><p>&nbsp;</p><p>The combined use of psychostimulants (e.g. methylphenidate) with paliperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Plasma exposure to paliperidone after a single dose of BYANNLI is expected to remain for up to 4 years (see section 5.2). This should be taken into account when initiating treatment in women of</p><p>childbearing potential, considering a possible future pregnancy or breast-feeding. BYANNLI should only be used in women planning to become pregnant if clearly necessary.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of paliperidone during pregnancy. Intramuscularly injected paliperidone palmitate and orally administered paliperidone were not teratogenic in animal studies, but other types of reproductive toxicity were seen (see section 5.3). Neonates exposed to paliperidone during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>&nbsp;</p><p>Paliperidone has been detected in plasma up to 18 months after a single dose of the 3-monthly paliperidone palmitate injectable. Plasma exposure to paliperidone after a single dose of BYANNLI is expected to remain for up to 4 years (see section 5.2). Maternal exposure to BYANNLI before and during pregnancy may lead to adverse reactions in the newborn child. BYANNLI should not be used during pregnancy unless clearly necessary.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Paliperidone is excreted in the breast milk to such an extent that effects on the breast-fed infant are likely if therapeutic doses are administered to breast-feeding women. Since a single dose of BYANNLI is expected to remain for up to 4 years in plasma (see section 5.2), breast-fed infants may be at risk even from BYANNLI administration long before breast-feeding. Patients currently under treatment or who have been treated in the past 4 years with BYANNLI should not breast feed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There were no relevant effects observed in the non-clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paliperidone has minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred (see</p><p>section 4.8). Therefore, patients should be advised not to drive or operate machines until their individual susceptibility to BYANNLI is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently observed adverse reactions reported in &ge; 5% of patients in the randomised double-blind active controlled clinical trial of BYANNLI were upper respiratory tract infection, injection site reaction, weight increased, headache and Parkinsonism.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following are all adverse reactions that were reported with paliperidone by frequency category estimated from paliperidone palmitate clinical trials. The following terms and frequencies are applied: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare</p><p>(&ge; 1/10 000 to &lt; 1/1 000); very rare (&lt; 1/10 000); and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and</strong></p></td><td rowspan="10" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>upper respiratory tract</p></td><td style="vertical-align:top"><p>pneumonia,</p></td><td style="vertical-align:top"><p>eye infection,</p></td><td rowspan="10" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>infestations</strong></p></td><td style="vertical-align:top"><p>infection, urinary tract</p><p>infection, influenza</p></td><td style="vertical-align:top"><p>bronchitis,</p><p>respiratory tract</p></td><td style="vertical-align:top"><p>acarodermatitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infection, sinusitis,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cystitis, ear</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infection,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tonsillitis,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>onychomycosis,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cellulitis,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>subcutaneous</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abscess</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>white blood cell</p></td><td style="vertical-align:top"><p>neutropenia,</p></td><td style="vertical-align:top"><p>agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>lymphatic </strong><strong>system disorders</strong></p></td><td style="vertical-align:top"><p>count decreased,</p><p>anaemia</p></td><td style="vertical-align:top"><p>thrombocytopenia,</p><p>eosinophil count increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune </strong><strong>system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine</strong></p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperprolactinaemia<sup>b</sup></p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>inappropriate</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>antidiuretic</p><p>hormone secretion,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>glucose urine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>present</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and</strong></p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperglycaemia, weight</p></td><td style="vertical-align:top"><p>diabetes mellitus<sup>d</sup>,</p></td><td style="vertical-align:top"><p>diabetic</p></td><td style="vertical-align:top"><p>water intoxication</p></td></tr><tr><td style="vertical-align:top"><p><strong>nutrition disorders</strong></p></td><td style="vertical-align:top"><p>increased, weight</p><p>decreased, decreased</p></td><td style="vertical-align:top"><p>hyperinsulinaemia,</p><p>increased appetite,</p></td><td style="vertical-align:top"><p>ketoacidosis,</p><p>hypoglycaemia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>appetite</p></td><td style="vertical-align:top"><p>anorexia, blood</p></td><td style="vertical-align:top"><p>polydipsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>triglycerides</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased, blood</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cholesterol</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong></p></td><td style="vertical-align:top"><p>insomnia<sup>e</sup></p></td><td style="vertical-align:top"><p>agitation, depression,</p></td><td style="vertical-align:top"><p>sleep disorder,</p></td><td style="vertical-align:top"><p>catatonia,</p></td><td style="vertical-align:top"><p>sleep-related</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anxiety</p></td><td style="vertical-align:top"><p>mania, libido</p><p>decreased,</p></td><td style="vertical-align:top"><p>confusional state,</p><p>somnambulism,</p></td><td style="vertical-align:top"><p>eating disorder</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>nervousness,</p></td><td style="vertical-align:top"><p>blunted affect,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>nightmare</p></td><td style="vertical-align:top"><p>anorgasmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:109px"><p><strong>Nervous </strong><strong>system disorders</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>parkinsonism,</p><p>akathisiac, sedation/ somnolence, dystoniac, dizziness, dyskinesiac, tremor, headache</p></td><td style="vertical-align:top; width:125px"><p>tardive dyskinesia, syncope, psychomotor hyperactivity, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top; width:139px"><p>neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, convulsion<sup>e</sup>, balance disorder, coordination abnormal, head</p><p>titubation</p></td><td style="vertical-align:top; width:114px"><p>diabetic coma</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Eye disorders</strong></p></td><td rowspan="6" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>vision blurred,</p><p>conjunctivitis, dry</p></td><td style="vertical-align:top; width:139px"><p>glaucoma, eye</p><p>movement disorder,</p></td><td style="vertical-align:top; width:114px"><p>floppy iris</p><p>syndrome</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>eye</p></td><td style="vertical-align:top; width:139px"><p>eye rolling,</p></td><td style="vertical-align:top; width:114px"><p>(intraoperative)</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>photophobia,</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>lacrimation</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>increased, ocular</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>hyperaemia</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Ear and labyrinth</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>vertigo, tinnitus, ear pain</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Cardiac disorders</strong></p></td><td rowspan="11" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>tachycardia</p></td><td style="vertical-align:top; width:125px"><p>atrioventricular</p><p>block, conduction</p></td><td style="vertical-align:top; width:139px"><p>atrial fibrillation,</p><p>sinus arrhythmia</p></td><td rowspan="11" style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>disorder,</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>electrocardiogram</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>QT prolonged,</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>postural orthostatic</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>tachycardia</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>syndrome,</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>bradycardia,</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>electrocardiogram</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>abnormal,</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>palpitations</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>hypertension</p></td><td style="vertical-align:top; width:125px"><p>hypotension, orthostatic hypotension</p></td><td style="vertical-align:top; width:139px"><p>pulmonary embolism, venous thrombosis,</p><p>flushing</p></td><td style="vertical-align:top; width:114px"><p>ischaemia</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Respiratory,</strong></p></td><td rowspan="4" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>cough, nasal congestion</p></td><td style="vertical-align:top; width:125px"><p>dyspnoea,</p></td><td style="vertical-align:top; width:139px"><p>sleep apnoea</p></td><td style="vertical-align:top; width:114px"><p>hyperventilation,</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>pharyngolaryngeal</p><p>pain, epistaxis</p></td><td style="vertical-align:top; width:139px"><p>syndrome,</p><p>pulmonary congestion, respiratory tract</p></td><td style="vertical-align:top; width:114px"><p>pneumonia</p><p>aspiration, dysphonia</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>congestion, rales,</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>wheezing</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Gastrointestinal</strong></p></td><td rowspan="5" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>abdominal pain,</p></td><td style="vertical-align:top; width:125px"><p>abdominal</p></td><td style="vertical-align:top; width:139px"><p>pancreatitis,</p></td><td style="vertical-align:top; width:114px"><p>ileus</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>disorders</strong></p></td><td style="vertical-align:top; width:145px"><p>vomiting, nausea,</p><p>constipation, diarrhoea,</p></td><td style="vertical-align:top; width:125px"><p>discomfort,</p><p>gastroenteritis,</p></td><td style="vertical-align:top; width:139px"><p>intestinal</p><p>obstruction,</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>dyspepsia, toothache</p></td><td style="vertical-align:top; width:125px"><p>dysphagia, dry</p></td><td style="vertical-align:top; width:139px"><p>swollen tongue,</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>mouth, flatulence</p></td><td style="vertical-align:top; width:139px"><p>faecal incontinence,</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>faecaloma, cheilitis</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Hepatobiliary</strong></p></td><td rowspan="4" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>transaminases increased</p></td><td style="vertical-align:top; width:125px"><p>gamma-</p></td><td rowspan="4" style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>jaundice</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>disorders</strong></p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>glutamyltransferas</p><p>e increased,</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>hepatic enzyme</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>increased</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Skin and</strong></p></td><td rowspan="4" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>urticaria, pruritus,</p></td><td style="vertical-align:top; width:139px"><p>drug eruption,</p></td><td style="vertical-align:top; width:114px"><p>Stevens-Johnson</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>subcutaneous </strong><strong>tissue disorders</strong></p></td><td style="vertical-align:top; width:125px"><p>rash, alopecia,</p><p>eczema, dry skin, erythema, acne</p></td><td style="vertical-align:top; width:139px"><p>hyperkeratosis,</p><p>seborrhoeic dermatitis, dandruff</p></td><td style="vertical-align:top; width:114px"><p>syndrome/toxic</p><p>epidermal necrolysis,</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>angioedema, skin</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>discolouration</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>Musculoskeletal</strong></p></td><td rowspan="4" style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>musculoskeletal pain,</p></td><td style="vertical-align:top; width:125px"><p>blood creatine</p></td><td style="vertical-align:top; width:139px"><p>rhabdomyolysis,</p></td><td style="vertical-align:top; width:114px"><p>posture abnormal</p></td></tr><tr><td style="vertical-align:top; width:109px"><p><strong>and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:145px"><p>back pain, arthralgia</p></td><td style="vertical-align:top; width:125px"><p>phosphokinase</p><p>increased, muscle spasms, joint</p></td><td style="vertical-align:top; width:139px"><p>joint swelling</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>stiffness, muscular</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:145px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>weakness</p></td><td style="vertical-align:top; width:139px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:108px"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:146px"><p>&nbsp;</p></td><td style="vertical-align:top; width:127px"><p>urinary incontinence,</p><p>pollakiuria, dysuria</p></td><td style="vertical-align:top; width:138px"><p>urinary retention</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:108px"><p><strong>Pregnancy, puerperium and perinatal</strong></p><p><strong>conditions</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:146px"><p>&nbsp;</p></td><td style="vertical-align:top; width:127px"><p>&nbsp;</p></td><td style="vertical-align:top; width:138px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td style="vertical-align:top; width:108px"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:146px"><p>amenorrhoea</p></td><td style="vertical-align:top; width:127px"><p>erectile dysfunction, ejaculation disorder, menstrual disorder<sup>e</sup>, gynaecomastia, galactorrhoea, sexual dysfunction,</p><p>breast pain</p></td><td style="vertical-align:top; width:138px"><p>priapism,breast discomfort, breast engorgement, breast enlargement, vaginal discharge</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:108px"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:146px"><p>pyrexia, asthenia, fatigue, injection site reaction</p></td><td style="vertical-align:top; width:127px"><p>face oedema, oedemae, body temperature increased, gait abnormal, chest pain, chest discomfort, malaise, induration</p></td><td style="vertical-align:top; width:138px"><p>hypothermia, chills, thirst, drug withdrawal syndrome, injection site abscess, injection site cellulitis, injection</p><p>site cyst, injection site haematoma</p></td><td style="vertical-align:top; width:118px"><p>body temperature decreased, injection site necrosis, injection site ulcer</p></td></tr><tr><td style="vertical-align:top; width:108px"><p><strong>Injury, </strong><strong>poisoning and procedural</strong></p><p><strong>complications</strong></p></td><td style="vertical-align:top; width:83px"><p>&nbsp;</p></td><td style="vertical-align:top; width:146px"><p>&nbsp;</p></td><td style="vertical-align:top; width:127px"><p>fall</p></td><td style="vertical-align:top; width:138px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The frequency of adverse reactions is qualified as &ldquo;not known&rdquo; because they were not observed in paliperidone palmitate</p><p>clinical trials. They were either derived from spontaneous post-marketing reports and frequency cannot be determined, or they were derived from risperidone (any formulation) or oral paliperidone clinical trials data and/or post-marketing reports.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to &lsquo;Hyperprolactinaemia&rsquo; below.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to &lsquo;Extrapyramidal symptoms&rsquo; below.</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In placebo-controlled trials, diabetes mellitus was reported in 0.32% in subjects treated with 1-monthly paliperidone palmitate injectable compared to a rate of 0.39% in placebo group. Overall incidence from all clinical trials was 0.65% in all subjects treated 1-monthly paliperidone palmitate injectable.</p><p><strong>e&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Insomnia includes: </strong>initial insomnia, middle insomnia; <strong>Convulsion includes: </strong>grand mal convulsion; <strong>Oedema includes:</strong></p><p>generalised oedema, oedema peripheral, pitting oedema; <strong>Menstrual disorder includes: </strong>menstruation delayed, menstruation irregular, oligomenorrhoea.</p><p>&nbsp;</p><p><u>Undesirable effects noted with risperidone formulations</u></p><p>&nbsp;</p><p>Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Anaphylactic reaction</em></p><p>Rarely, cases of anaphylactic reaction after injection with 1-monthly paliperidone palmitate injectable have been reported during post-marketing experience in patients who have previously tolerated oral risperidone or oral paliperidone (see section 4.4).</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>In the clinical trial of BYANNLI, 10.7% of subjects reported injection site related adverse reaction (4.5% in subjects treated with the comparator 3-monthly paliperidone palmitate injectable). None of these events were serious or led to discontinuation. Based on the investigators&rsquo; clinical ratings, induration, redness, and swelling were absent or mild in &ge; 95% of the assessments. Subject-rated injection site pain based on a visual analogue scale was low and decreased in intensity over time.</p><p>&nbsp;</p><p><em>Extrapyramidal symptoms (EPS)</em></p><p>In the clinical trial of BYANNLI, akathisia, dyskinesia, dystonia, parkinsonism, and tremor were reported in 3.6%, 1.5%, 0.6%, 5.0%, and 0.2% of subjects, respectively.</p><p>&nbsp;</p><p>EPS included a pooled analysis of the following terms: parkinsonism (includes extrapyramidal disorder, extrapyramidal symptoms, on and off phenomenon, Parkinson&rsquo;s disease, parkinsonian crisis, salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, glabellar reflex abnormal, and parkinsonian rest tremor), akathisia (includes akathisia, restlessness, hyperkinesia, and restless leg syndrome), dyskinesia (includes dyskinesia, chorea, movement disorder, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia (includes dystonia, cervical spasm, emprosthotonus, oculogyric crisis, oromandibular dystonia, risus sardonicus, tetany, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus), and tremor (includes tremor, action tremor).</p><p>&nbsp;</p><p><em>Changes in body weight</em></p><p>In the 12-month clinical trial of BYANNLI, the number of subjects with abnormal weight percent change from double-blind baseline to double-blind end point is presented in the table below. The overall mean weight change from double-blind baseline to double-blind end point was +0.10 kg for the BYANNLI group and +0.96 kg for the 3-monthly paliperidone palmitate group. In subjects</p><p>18-25 years of age, mean (SD) weight change of -0.65 (4.955) kg was observed for the BYANNLI group and +4.33 (7.112) kg in the 3-monthly paliperidone palmitate group. For overweight subjects (BMI 25 to &lt; 30), mean weight change of -0.53 kg in the BYANNLI group and +1.15 kg in the</p><p>3-monthly paliperidone palmitate group was observed.</p><p>&nbsp;</p><p><strong>Number of patients with abnormal weight percent change from (double-blind) baseline to end point</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Weight percent change</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>PP3M<sup>1</sup></p><p>(N=219)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>BYANNLI</p><p>(N=473)</p></td></tr><tr><td style="vertical-align:top"><p>Decrease &ge; 7%</p></td><td style="vertical-align:top"><p>15 (6.8%)</p></td><td style="vertical-align:top"><p>43 (9.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Increase &ge; 7%</p></td><td style="vertical-align:top"><p>29 (13.2%)</p></td><td style="vertical-align:top"><p>50 (10.6%)</p></td></tr></tbody></table><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PP3M &ndash; 3-monthly paliperidone palmitate injectable</p><p>&nbsp;</p><p><em>Hyperprolactinaemia</em></p><p>In the 12-month clinical trial of BYANNLI, the mean (SD) change from double-blind baseline in prolactin levels was -2.19 (13.61) &micro;g/L for males and -4.83 (34.39) &micro;g/L for females in the 6-monthly paliperidone palmitate group and in the 3-monthly paliperidone palmitate group it was</p><p>1.56 (19.08)◦&micro;g/L for males and 9.03 (40.94) &micro;g/L for females. During the double-blind phase, 3 females (4.3%) in the 3-monthly paliperidone palmitate group and 5 females (3.3%) in the</p><p>6- monthly paliperidone palmitate group experienced amenorrhoea. <u>Class effects</u></p><p>QT prolongation, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), sudden unexplained death, cardiac arrest, and Torsade de pointes may occur with antipsychotics.</p><p>&nbsp;</p><p>Cases of VTE, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotic medicinal products (frequency unknown).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medical product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>To reports any side effect(s):</p><p>&nbsp;</p><p>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SAUDI ARABIA:</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:71.65pt;margin-top:14.55pt;width:455.55pt;height:82.3pt;
  z-index:-15728128;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.2pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:35.5pt;margin-bottom:.0001pt;text-indent:-10.4pt;
     mso-list:l3 level1 lfo3;tab-stops:35.55pt'><![if !supportLists]><span
     lang=EN-US style='font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US style='letter-spacing:-.05pt'>The</span><span
     lang=EN-US style='letter-spacing:-.5pt'> </span><span lang=EN-US>National<span
     style='letter-spacing:-.4pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.45pt'> </span>Centre<span style='letter-spacing:
     -.7pt'> </span>(NPC):<o:p></o:p></span></p>
     <p class=MsoBodyText><span lang=EN-US><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:35.5pt;text-indent:-10.4pt;
     line-height:13.2pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo2;
     tab-stops:35.55pt'><![if !supportLists]><span lang=EN-US style='font-family:
     "Calibri","sans-serif";mso-fareast-font-family:Calibri'><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-US>SFDA<span
     style='letter-spacing:-.5pt'> </span>Call<span style='letter-spacing:-.25pt'>
     </span>Center:<span style='letter-spacing:-.4pt'> </span>19999<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:35.5pt;text-indent:-10.4pt;
     line-height:13.15pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo2;
     tab-stops:35.55pt'><![if !supportLists]><span lang=EN-US style='font-family:
     "Calibri","sans-serif";mso-fareast-font-family:Calibri'><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='letter-spacing:-.05pt;mso-ansi-language:FR'>E-mail:</span><span
     style='color:#0000FC;letter-spacing:-.6pt;mso-ansi-language:FR'> </span><span
     lang=EN-US><a href="mailto:npc.drug@sfda.gov.sa"><span lang=FR
     style='color:#0000FC;mso-ansi-language:FR'>npc.drug@sfda.gov.sa</span></a></span><span
     style='mso-ansi-language:FR'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:35.5pt;text-indent:-10.4pt;
     line-height:13.35pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo2;
     tab-stops:35.55pt'><![if !supportLists]><span lang=EN-US style='font-family:
     "Calibri","sans-serif";mso-fareast-font-family:Calibri'><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-US
     style='letter-spacing:-.05pt'>Website:</span><span lang=EN-US
     style='color:#0000FC;letter-spacing:-.55pt'> </span><span lang=EN-US><a
     href="https://ade.sfda.gov.sa/"><span style='color:#0000FC'>https://ade.sfda.gov.sa/</span></a><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/<strong style="text-align:unset">&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p><strong>&nbsp;-&nbsp;</strong>Please contact the relevant competent authority.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:69.15pt;
  margin-top:11.65pt;width:388.15pt;height:20.1pt;z-index:-15727616;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".82pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:2.3pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:10.25pt;margin-bottom:.0001pt'><span lang=EN-US
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt;position:relative;
     top:1.5pt;mso-text-raise:-1.5pt'>–<span style='letter-spacing:-.8pt'> </span></span><span
     lang=EN-US style='font-size:10.0pt;mso-bidi-font-size:11.0pt'>Please<span
     style='letter-spacing:-.5pt'> </span>contact<span style='letter-spacing:
     -.4pt'> </span>the<span style='letter-spacing:-.8pt'> </span>relevant<span
     style='letter-spacing:-.5pt'> </span>competent<span style='letter-spacing:
     -.4pt'> </span>authority.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>In general, expected signs and symptoms are those resulting from an exaggeration of paliperidone&rsquo;s known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, QT prolongation, and extrapyramidal symptoms. Torsade de pointes and ventricular fibrillation have been reported in a patient in the setting of overdose with oral paliperidone. In the case of acute overdose, the possibility of multiple drug involvement should be considered.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>Consideration should be given to the long-acting nature of the medicinal product and the long elimination half-life of paliperidone when assessing treatment needs and recovery. There is no specific antidote to paliperidone. General supportive measures should be employed. Establish and maintain a clear airway and ensure adequate oxygenation and ventilation.</p><p>&nbsp;</p><p>Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring for possible arrhythmias. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluid and/or sympathomimetic agents. In case of severe extrapyramidal symptoms, anticholinergic agents should be administered. Close supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psycholeptics, other antipsychotics. ATC code: N05AX13 BYANNLI contains a racemic mixture of (+)- and (-)-paliperidone.</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Paliperidone is a selective blocking agent of monoamine effects, whose pharmacological properties are different from that of traditional neuroleptics. Paliperidone binds strongly to serotonergic 5-HT2-</p><p>&nbsp;</p><p>and dopaminergic D2-receptors. Paliperidone also blocks alpha 1-adrenergic receptors and slightly less, H1-histaminergic and alpha 2-adrenergic receptors. The pharmacological activity of the (+)- and (-)-paliperidone enantiomers are qualitatively and quantitatively similar.</p><p>&nbsp;</p><p>Paliperidone is not bound to cholinergic receptors. Even though paliperidone is a strong</p><p>D2-antagonist, which is believed to relieve the symptoms of schizophrenia, it causes less catalepsy and decreases motor functions less than traditional neuroleptics. Dominating central serotonin antagonism may reduce the tendency of paliperidone to cause extrapyramidal side effects.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p>The efficacy of BYANNLI for the treatment of schizophrenia in patients who had previously been adequately treated with either 1-monthly paliperidone palmitate injection for at least 4 months or</p><p>3-monthly paliperidone palmitate injectable for at least one 3-month injection cycle was evaluated in a Phase 3, randomised, double-blind, active-controlled, interventional, parallel-group, multicentre,</p><p>non-inferiority study in adult patients. The primary outcome was time to relapse.</p><p>&nbsp;</p><p>The study consisted of an open-label phase which included screening, transition and maintenance phases, followed by a 12-month double-blind phase in which patients were randomised to receive either BYANNLI or 3-monthly paliperidone palmitate injectable. 702 adequately treated patients were randomised in a 2:1 ratio to receive BYANNLI (478 patients) or 3-monthly paliperidone palmitate injectable (224 patients). Patients received either 2 injection cycles of BYANNLI (4 injections in total; BYANNLI with alternating placebo) or 4 injections of 3-monthly paliperidone palmitate injection every 3 months with regular scheduled visits between injections over the 12-month study duration.</p><p>Dose adjustment was not permitted during the double-blind phase. Patients remained in this phase until they experienced a relapse event, met discontinuation/withdrawal criteria, or study conclusion.</p><p>&nbsp;</p><p>7.5% of patients in the BYANNLI treatment group and 4.9% of patients in the 3-monthly paliperidone palmitate injectable treatment group experienced a relapse event in the 12-month double-blind Phase with the Kaplan-Meier estimated difference (BYANNLI &ndash; 3-monthly paliperidone palmitate injection) of 2.9% (95% CI: -1.1% to 6.8%). The Kaplan-Meier plot (with 95% pointwise confidence bands) of time from randomisation to impending relapse during the 12-month double-blind, active-controlled Phase for BYANNLI 700 and 1 000 mg and 3-monthly paliperidone palmitate injectable 350 mg and 525 mg is shown in Figure 1.</p><p><img src="data:image/png;base64,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" alt="" width="823" height="464" vspace="0" hspace="0" border="0" style="width:823px;height:464px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>The efficacy results were consistent across population subgroups (gender, age, and race) in both treatment arms.</p><p>&nbsp;</p><p>It was determined that the efficacy of BYANNLI was noninferior to the efficacy of 3-monthly paliperidone palmitate injection in adults with a DSM-5 diagnosis of schizophrenia. The upper bound of the 95% CI (6.8%) was less than 10%, the prespecified non-inferiority margin.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with BYANNLI in all subsets of the paediatric population in schizophrenia (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics for BYANNLI are presented after gluteal administration only. <u>Absorption and distribution</u></p><p>Due to its extremely low water solubility, the 6-monthly formulation of paliperidone palmitate dissolves slowly after intramuscular injection before being hydrolysed to paliperidone and absorbed into the systemic circulation. The release of the active substance after a single dose of 3-monthly paliperidone palmitate injectable starts as early as day 1 and lasts for as long as 18 months. The release of BYANNLI is expected to last longer. Paliperidone plasma concentrations have only been studied up to 6 months after administration of BYANNLI. Based on population pharmacokinetic simulations paliperidone concentrations are expected to remain in plasma for up to approximately 4 years following a single 1 000 mg dose of BYANNLI. The concentration of paliperidone remaining in the circulation approximately 4 years after a single dose of 1 000 mg BYANNLI is expected to be</p><p>low (&lt; 1% of the average steady state levels).</p><p>&nbsp;</p><p>The data presented in this paragraph are based on a population pharmacokinetic analysis. Following a single gluteal intramuscular injection of BYANNLI at doses of 700 and 1 000 mg, the plasma concentrations of paliperidone gradually rise to reach maximum plasma concentrations predicted on days 33 and 35, respectively. The release profile and dosing regimen of BYANNLI results in sustained therapeutic concentrations over 6 months. Cmax and AUC6month of BYANNLI were approximately</p><p>dose-proportional in the range of 700-1 000 mg. The median steady-state peak:trough ratio is approximately 3.0.</p><p>The plasma protein binding of racemic paliperidone is 74%. <u>Biotransformation and elimination</u></p><p>In a study with oral immediate release <sup>14</sup>C-paliperidone, one week following administration of a single oral dose of 1 mg immediate release <sup>14</sup>C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised in the liver. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the faeces. Four metabolic pathways have been identified <em>in vivo</em>, none of which accounted for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Although <em>in vitro </em>studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, there is no evidence <em>in vivo </em>that these isozymes play a significant role in the metabolism of paliperidone. Population pharmacokinetics analyses indicated no discernible difference on the apparent clearance of paliperidone after administration of oral paliperidone between extensive metabolisers and poor metabolisers of CYP2D6 substrates. <em>In vitro </em>studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5.</p><p>&nbsp;</p><p><em>In vitro </em>studies have shown that paliperidone is a P-gp substrate and a weak inhibitor of P-gp at high concentrations. No <em>in vivo </em>data are available and the clinical relevance is unknown.</p><p>&nbsp;</p><p>Based on population pharmacokinetic analysis, the median apparent half-life of paliperidone following BYANNLI gluteal administration at doses of 700 and 1 000 mg is estimated to be 148 and 159 days, respectively.</p><p>&nbsp;</p><p><u>Long-acting 6-monthly paliperidone palmitate injection versus other paliperidone formulations</u></p><p>&nbsp;</p><p>BYANNLI is designed to deliver paliperidone over a 6-month period, compared to the 1-monthly or 3-monthly products which are administered every month or every three months, respectively.</p><p>BYANNLI doses of 700 mg and 1 000 mg results in a range of paliperidone exposures similar to those obtained with corresponding doses of 1-monthly or 3-monthly paliperidone palmitate injections or corresponding once daily doses of paliperidone prolonged-release tablets (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Paliperidone is not extensively metabolised in the liver. Although BYANNLI was not studied in patients with hepatic impairment, no dose adjustment is required in patients with mild or moderate hepatic impairment. In a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects. Paliperidone has not been studied in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>BYANNLI has not been systematically studied in patients with renal impairment. The disposition of a single oral dose of a paliperidone 3 mg prolonged-release tablet was studied in subjects with varying degrees of renal function. Elimination of paliperidone decreased with decreasing estimated creatinine clearance. Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 to &le; 80 mL/min), 64% in moderate (CrCl = 30 to &le; 50 mL/min), and 71% in severe (CrCl = 10 to &lt; 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUCinf) of 1.5, 2.6, and 4.8-fold, respectively, compared to healthy subjects.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>Population pharmacokinetics analysis showed no evidence of age related pharmacokinetics differences.</p><p>&nbsp;</p><p><u>Body mass index (BMI)/body weight</u></p><p>&nbsp;</p><p>Lower Cmax was observed in overweight and obese subjects. At apparent steady-state with BYANNLI, the trough concentrations were similar among normal, overweight, and obese subjects.</p><p>&nbsp;</p><p><u>Race</u></p><p>&nbsp;</p><p>Pharmacokinetic analysis showed no evidence of clinically relevant difference in pharmacokinetics between races.</p><p>&nbsp;</p><p><u>Gender</u></p><p>&nbsp;</p><p>Population pharmacokinetics analysis showed no evidence of gender related pharmacokinetics differences.</p><p>&nbsp;</p><p><u>Smoking status</u></p><p>&nbsp;</p><p>Based on <em>in vitro </em>studies utilising human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone. Effect of smoking on the pharmacokinetics of paliperidone was not studied with BYANNLI. A population pharmacokinetic analysis based on data with oral paliperidone prolonged-release tablets showed a slightly lower exposure to paliperidone in smokers compared with non-smokers. The difference is not likely to be of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat-dose toxicity studies of intramuscularly injected paliperidone palmitate (the 1-monthly formulation) and orally administered paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals. In animals treated with paliperidone palmitate an inflammatory reaction was seen at the intramuscular injection site. Occasionally abscess formation occurred.</p><p>&nbsp;</p><p>In rat reproduction studies with oral risperidone, which is extensively converted to paliperidone in rats and humans, adverse effects were seen on the birth weight and survival of the offspring. No embryotoxicity or malformations were observed following intramuscular administration of paliperidone palmitate to pregnant rats up to the highest dose (160 mg/kg/day) corresponding to</p><p>1.6 times the exposure level in humans at the maximum recommended dose of 1 000 mg. Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring.</p><p>&nbsp;</p><p>Paliperidone palmitate and paliperidone were not genotoxic. In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. The carcinogenic potential of intramuscularly injected paliperidone palmitate was assessed in rats. There was a statistically significant increase in mammary gland adenocarcinomas in female rats at 10, 30 and 60 mg/kg/month. Male rats showed a statistically significant increase in mammary gland adenomas and carcinomas at 30 and 60 mg/kg/month which is 0.3 and 0.6 times the exposure level at the maximum recommended human 1 000 mg dose. These tumours can be related to prolonged dopamine D2-antagonism and hyperprolactinaemia. The relevance of these tumour findings in rodents in terms of human risk is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polysorbate 20</p><p>Polyethylene glycol 4 000 Citric acid monohydrate</p><p>Sodium dihydrogen</p><p>phosphate monohydrate</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30˚C.</p><p>Ship and store in a horizontal position. See arrows on product carton for proper orientation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>700 mg</u></p><p>3.5 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, plunger rod, backstop, and tip cap (bromobutyl rubber) with a thin wall 20G 1&frac12; inch (0.9 mm &times; 38 mm) safety needle.</p><p>&nbsp;</p><p><u>1 000 mg</u></p><p>5 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, plunger rod, backstop, and tip cap (bromobutyl rubber) with a thin wall 20G 1&frac12; inch (0.9 mm &times; 38 mm) safety needle.</p><p>&nbsp;</p><p><strong>Pack sizes:</strong></p><p>Pack contains 1 pre-filled syringe and 1 needle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ship and store this product in a horizontal orientation to improve the ability to resuspend this highly concentrated product and prevent clogging of the needle.</p><p>Shake the syringe very fast for at least 15 seconds, rest briefly, then shake again for 15 seconds. The suspension should be visually inspected before injection. When mixed well the product is uniform, thick and milky white. Full instructions for use and handling of BYANNLI are provided in the package leaflet (See <em>Information intended for healthcare professionals</em>).</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen-Cilag International NV 
Turnhoutseweg 30
B-2340 Beerse Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This leaflet was last revised in 25 May 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>